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Chapter 1  General introduction 
It is well known that around 15% of the patients with pancreatic cancer develop 
diabetes mellitus (DM) prior to the detection of their malignancy. In our population of 
diabetic patients at the ErasmusMC we investigated whether we could identify patients 
with pancreatic cancer. In this relatively small population of around 2500 patients, we 
could not find enough patients who were diagnosed with pancreatic cancer, but a high 
proportion of patients had other forms of cancer. Therefore we started to inquire the 
relation between DM and cancer incidence and cancer mortality. 
Over the past decades, wealth has increased and this has had its impact on the general 
health of the worldwide population and on health care as well. Below the major issues 
with regard to the changes in population health will be discussed in the light of this 
thesis. 
Obesity
Worldwide, the population has become increasingly obese; since 1980 obesity has nearly 
doubled up to 1.4 billion people of 20 years and older who were overweight in 2008 
(1). Overweight and obesity are defined as abnormal or excessive fat accumulation that 
may impair health. Overweight is further defined as a body mass index (BMI) equal or 
more than 25 and a BMI equal to or more than 30 is called obesity (1). Forecasts predict 
an ongoing increase in obesity prevalence over the next decades (figure 1), with serious 
implications regarding worldwide health and healthcare costs (2). 
Figure 1. Obesity forecasts. WHO and OECD Health data 2008.
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Metabolic syndrome
Following the abovementioned increase in obesity, the metabolic syndrome (MetS) 
has become a common clinical condition. MetS is a cluster of metabolic disorders with 
major risk factors being physical inactivity and high-fat diet. The main clinical features 
are central (or abdominal) obesity, insulin resistance, hypertension and dyslipidemia (3, 
4). However, the exact definition of MetS is still debated. Nevertheless it is thought that 
20% of adults in the Western world have MetS and that people with MetS have a five 
times higher risk of developing type 2 diabetes mellitus (T2DM) (3). With the predicted 
increase of obesity prevalence rates of MetS are expected to rise as well, which will be 
accompanied by major socioeconomic problems. 
Diabetes mellitus
The prevalence of T2DM has increased due to the rise in obesity and MetS since these 
conditions are related (5). Nowadays, 382 million people worldwide have diabetes 
mellitus (6). DM was given its name by the Greek physicians Apollonius Memphites and 
Aretaeus of Cappadocia in 250 before Christ. Diabetes comes from the Greek words ‘dia’, 
which means ‘through’ and from ‘baino’, which means ‘to go’. ‘Mellitus’ is a Latin word 
and means ‘honey’ or ‘sweet’ and was later added to the name of this disease. So literally, 
diabetes mellitus means ‘sweet flow’, referring to the sweet taste of the urine of diabetic 
patients, which was usually tasted by the physicians in order to obtain the diagnosis. 
DM exists of two major forms. Type 1 diabetes (T1DM) is an autoimmune condition 
characterized by an absolute insulin deficiency and requires daily insulin administration 
(7). The abovementioned T2DM accounts for 90% of diabetic cases worldwide and 
results from insulin resistance, which is present in obesity. Patients with T2DM may be 
treated with diet, exercise, oral glucose-lowering drugs (OGLD, like metformin or SU-
derivatives) or insulin (7).  Pancreatogenic diabetes or new-onset diabetes (NODM) 
is another form of T2DM and occurs in case of pancreatic disease or after pancreatic 
surgery (8). 
Forecasts, recently presented by the World Health Organisation, predict that DM will 
be the 7th leading cause of death in 2030 (9). The latter two types of T2DM (insuline 
resistance and pancreatogenic diabetes) will be the focus of this thesis.
Obesity, metabolic syndrome, T2DM and cancer 
It might be clear that obesity, MetS and T2DM are highly related. These three 
conditions share common factors; for instance hyperinsulinemia, hyperglycemia, altered 
adipocytokine levels and an increased state of inflammation (10). It is thought that these 
factors contribute – individually or collectively – to cancer development. 
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Hyperinsulinemia develops following insulin resistance which is present in obesity in an 
attempt to maintain euglycemia when tissues have reduced sensitivity to insulin (11). 
Insulin promotes cell proliferation and inhibits apoptosis by its receptor and insulin-like 
growth factors (IGF-I and -II) through the phosphoinositide 3-kinase/Akt, mitogen-
activated protein kinase and mTOR pathways (12, 13). In chapter 4 we assess the 
expression of the IGF-1 receptor in esophageal adenocarcinoma tissue and relate this to 
prognostic parameters. 
Glucose is known to be an important nutrient for proliferating cells and it is known 
that cancer cells take up more glucose (Warburg effect) (10, 13). The possibility that 
hyperglycemia facilitates cell proliferation therefore deserves consideration. However, 
most patients with T2DM suffer from hyperglycemia as well as hyperinsulinemia, 
and thus, separate effects of glucose and insulin are difficult to distinguish. Studies 
that indicate hyperglycemia as an independent risk factor are scarce and it is therefore 
thought that hyperglycemia mainly serves as a surrogate for other causative factors like 
hyperinsulinemia (14).
Adipose tissue has an active endocrine function; it secretes the adipokines leptin and 
adiponectin (10, 15). Leptin levels are increased in obesity and this stimulates tumor 
cell growth, migration, invasion and angiogenesis (10, 13, 16).  In contrast, adiponectin 
levels are decreased in obesity and normally have protective effects with regard to 
carcinogenesis; adiponectin decreases cell proliferation and increases apoptosis (10, 13, 
16). The pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukine-6 
(IL-6) are also secreted by adipose tissue (10, 15). Both cytokines are increased in obesity 
and stimulate angiogenesis, cell proliferation and inhibit apoptosis (16). Furthermore, 
TNF-α and IL-6 contribute to insulin resistance (15, 16) and are suppressed by 
adiponectin (10). This points out the intertwined relationship between the common 
factors of obesity, Met S and T2DM (figure 2).
Numerous studies have pointed out the increased risk of cancer and cancer mortality 
among patients with obesity and MetS with higher risks for e.g. esophageal 
adenocarcinoma, endometrial, pancreatic, postmenopausal breast and colorectal cancer 
(17-20). It has even been estimated that 20% of all cancer cases are caused by overweight 
and obesity (21).
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Figure 2. Carcinogenic effects of inflammation, adipokines and insulin resulting from obesity, metabolic 
syndrome (MetS) and type 2 diabetes mellitus (T2DM). Figure adapted and adjusted from Khandekar,  
et al. Nat Rev Cancer 2011;11:886-95.
With regard to T2DM, many studies have indicated T2DM as a risk factor - independent 
of obesity - for different types of cancer and mortality (14, 22-24). Breast, endometrial, 
colorectal, bladder, liver and pancreatic cancer have been consistently linked to T2DM, 
and interestingly, prostate cancer has been found to have an inverse relation with T2DM. 
In liver, pancreatic and endometrial cancer a twofold - or higher - risk has been described 
and for breast, colorectal, bladder a 1.2 to 1.5 fold increased risk has been seen. In liver 
and pancreatic cancer however, the association with T2DM can be discussed because 
reverse causality plays an important role with the cancer itself probably leading to the 
onset of the diabetes (14). 
This thesis will mainly focus on T2DM and its influence on the incidence and prognosis 
of common surgical malignancies, that is, breast, colorectal and esophageal cancer. In 
initial studies cancer-specific mortality was not extensively studied. Therefore we studied 
this more accurately in a meta-analysis; chapter 2 discusses cancer incidence and cancer-
specific mortality of the two most common surgical malignancies: breast and colorectal 
cancer. 
Despite the evidence regarding the association between T2DM and cancer seems 
convincing, important factors that need to be addressed are detection bias and diabetes 
duration. Detection bias occurs when there is increased surveillance of newly diagnosed 
diabetic patients which accounts for enhanced cancer detection (25). The fact that some 
studies found different cancer risks with varying durations of diabetes reflects the issue of 
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detection bias (26-28). In a cohort of the Rotterdam Study we further assessed detection 
bias and diabetes duration with regard to cancer incidence (chapter 3). 
Furthermore, DM treatment is thought to be of additional influence on cancer risk and 
mortality. Metformin has been said to decrease cancer risk and insulin is said to further 
increase cancer risk (29, 30). However, controversy on this topic exists and future studies 
should take into account epidemiological biases that can occur while performing studies 
on medication use (30, 31). The association of glucose-lowering drugs with cancer will 
not be further discussed in this thesis. 
Lastly, studies have shown that diabetic patients receive less optimal treatment in case 
of cancer (32-34), indicating cancer treatment selection. This might partially explain 
the diminished prognosis of diabetic patients with cancer compared to non-diabetics. 
In chapter 5 we assess the effect of DM on chances to undergo surgery and prognosis in 
patients with esophageal adenocarcinoma.
New-onset diabetes mellitus after pancreatic surgery
Another aspect of improved health care is that different imaging modalities are 
increasingly used in screening or routine examinations. This results in an enhanced 
detection of asymptomatic lesions (‘incidentalomas’) in different kind of organs that 
sometimes require surgical treatment (35, 36). This also concerns asymptomatic lesions 
of the pancreas which are detected with increased frequency (35). Because these lesions 
are relatively often situated in the pancreatic body or tail, distal pancreatectomy (37) is 
a procedure that is increasingly performed (38-40). DP is considered a safe procedure 
with low mortality rates (41, 42). However, morbidity is substantial, mainly consisting of 
postoperative pancreatic fistula and NODM (41-43). 
After pancreatic head resection, 20-40% of the patients will develop DM, depending on 
the underlying disease (43-45). Since exact percentages of NODM after DP were not 
known, we performed a systematic review to obtain exact percentages of NODM after 
DP (chapter 6). In chapter 7 the incidentaloma-rate among Dutch patients undergoing 
DP for various indications is assessed. By studying postoperative endo- and exocrine 
pancreatic function and quality of life the impact of DP and its complications in 
preoperative asymptomatic patients becomes clearer. 
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Chapter 2  A systematic review and meta-analysis on the association 
between diabetes mellitus and incidence and mortality in 
breast and colorectal cancer
K. M. J. De Bruijn, L. R. Arends, B. E. Hansen, S. Leeflang, R. Ruiter 
and C. H. J. van Eijck
British Journal of Surgery. 2013 Oct;100(11):1421-9
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Abstract
Background 
Increasing evidence suggests that diabetes mellitus (DM) is associated with increased 
cancer incidence and mortality. Several mechanisms involved in diabetes, such as 
promotion of cell proliferation and decreased apoptosis, may foster carcinogenesis. This 
study investigated the association between DM and cancer incidence and cancer-specific 
mortality in patients with breast and colorectal carcinoma.
Methods
A meta-analysis of controlled trials, prospective cohort studies and pooled cohort studies 
published after 2007 was conducted. Embase, PubMed and the Cochrane Library were 
searched. Summary hazard ratios (HRs) were calculated using a random-effects model. 
Sensitivity and subgroup analyses were performed to adjust for confounders, mode of 
DM assessment and follow-up time.
Results
Twenty studies were included to investigate the association between DM and breast and 
colorectal cancer incidence and cancer-specific mortality. The studies predominantly 
comprised patients with type II DM. The overall HR for breast cancer incidence was 1.23 
(95 per cent confidence interval 1.12 to 1.34) and that for colorectal cancer was 1.26 
(1.14 to 1.40) in patients with DM compared with those without diabetes. The overall 
HR was 1.38 (1.20 to 1.58) for breast cancer- and 1.30 (1.15 to 1.47) for colorectal 
cancer-specific mortality in patients with DM compared with those without diabetes. 
Conclusions
This meta-analysis indicated that DM is a risk factor for breast and colorectal cancer, and 
cancer-specific mortality. 
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Introduction 
Type II diabetes mellitus (DM) develops in obese people owing to insulin resistance, which 
is a compensatory mechanism for raised blood glucose levels (1). As the incidence of obesity 
is increasing (2), the incidence of DM is also rising. In surgical patients, obesity and diabetes 
are risk factors for perioperative and postoperative morbidity and mortality (3,4). 
There is also increasing evidence for an association between diabetes and cancer (5). 
Recent studies have shown that the incidence of breast, colorectal, pancreatic and 
oesophageal cancer is higher in people with diabetes, and these patients have a poorer 
prognosis (6–8). Several mechanisms involved in obesity and diabetes have been held 
responsible for the increased cancer incidence and worse prognosis (9). 
The adipokines in adipose tissue (leptin and adiponectin) exert effects on carcinogenesis 
(10,11). Insulin promotes cell proliferation and inhibits apoptosis by its receptor and 
insulin-like growth factors (IGF-I and -II) through the phosphoinositide 3-kinase/Akt, 
mitogen-activated protein kinase and mTORpathways (9,12). 
The impact of DM on cancer-specific mortality has rarely been studied. Therefore, the 
present meta-analysis of published studies focuses on the association between DM and 
cancer incidence as well as cancer-specific mortality in patients with breast cancer and 
colorectal carcinoma, two of the most common surgical malignancies. 
Methods
This meta-analysis was guided by the procedure proposed by Mahid and colleagues (13). 
Study selection criteria and search strategy
Inclusion and exclusion criteria were defined in a review protocol. Eligible studies were 
those that compared breast and/or colorectal cancer incidence and/or cancer-specific 
death between patients with and without DM, in which the hazard ratio (HR) was a 
primary outcome measure. Studies that included patients with type I DM only were 
excluded. Studies investigating patients without known DM, but that assessed DM by 
diagnostic blood tests (such as insulin, glucose or homeostatic model assessment score) 
were included in the analysis.
In August 2012, Embase, PubMed and the Cochrane Library were searched using the 
search terms ‘cancer incidence’, ‘cancer mortality’, ‘diabetes mellitus’, ‘insulin resistance’, 
‘hyperinsulinemia’, ‘oncogenesis’, ‘carcinogenesis’, ‘neoplasmogenesis’, ‘breast tumor’, ‘colon 
tumor’, ‘oesophageal tumor’, without year or language restrictions. Studies published 
between January 2007 and August 2012 with level I or II evidence according to the 
Oxford 2011 Levels of Evidence (14) (randomized clinical trials (RCTs), prospective 
cohort studies, pooled cohort studies), were included in the study. The methodological 
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quality of the included studies was assessed by means of the Jadad criteria for RCTs and 
the Newcastle–Ottawa scale for cohort studies (15,16).
Studies that seemed to fulfil the eligibility criteria and those for which information in 
the abstract was insufficient for exclusion were read in full. Bibliographies of included 
publications were searched for other studies and authors were contacted when additional 
unpublished data were needed for analysis. 
Data extraction
Two independent reviewers screened titles and abstracts, and full articles if necessary, 
of all citations retrieved from the searches and checked them for eligibility. Any 
disagreement was resolved until consensus was achieved.
The following data were extracted: HRs for breast and colorectal cancer incidence, and 
for breast and colorectal cancer-specific mortality, in patients with DM compared with 
those without. If available, the unadjusted HRs were selected for analysis. If unadjusted 
HRs were not available, the least adjusted HR was used. Multivariable adjusted HRs were 
pooled in additional analyses to compare them with the pooled unadjusted HRs.  DM 
was defined by the criteria for the specific study.
Statistical analysis
Analyses were performed with Comprehensive Meta-analysis® software version 2 (Biostat, 
Englewood, New Jersey, USA) and RevMan 5.1 (http://ims.cochrane.org/revman/
download). The pooled estimates for dichotomous variables are reported as HR with 
95 per cent confidence interval (c.i.). Meta-analyses were conducted using a random-
effects model. If a study contained subgroups of DM (such as quartiles) and consequently 
multiple HRs, one pooled HR was calculated from these subgroups and used in the final 
meta-analysis. If no HR was available, HRs and 95 per cent c.i. were calculated from the 
raw data and the mean follow-up of the study.
Between-study heterogeneity was assessed by means of the I2 value, with 25, 50 and 75 
per cent representing low, moderate and high heterogeneity respectively (17). Publication 
bias was assessed from funnel plots in which the log HR for each study was plotted 
against its standard error. Funnel plot symmetry was assessed both visually and formally 
with Egger’s test.
Sensitivity analyses were carried out to investigate the influence of each study on the 
overall outcome of the meta-analysis. In addition, several subgroup analyses were 
conducted; the first compared the unadjusted and adjusted HRs, the second examined 
the effect of mode of assessing DM, and the third explored the impact of the mean 
follow-up time on the overall HR.
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Results
A total of 20 studies published after 2007 were included in the meta-analysis, comprising 
1 930 309 individuals with predominantly type II DM (Fig. 1). 
Figure 1. PRISMA diagram showing selection of articles for review
Characteristics of the included studies are summarized in Table 1(18–37). There were 
17 prospective cohort studies (18–24,27,29–37), one randomized trial (25), and 
two articles that described pooled analyses of cohort studies (26,28). It appeared that 
there was overlap between the latter two studies and one of the cohort studies (23). 
Nevertheless, these two studies used random and different samples from the total cohort. 
The total number of overlapping cancer cases and deaths may therefore be expected to be 
minimal and to have little influence on overall outcome. Thus, the potentially overlapping 
study (23) was not excluded from the analysis. 
Six studies analysed the incidence of breast cancer, and six the incidence of colorectal 
cancer, in patients with DM. Eight studies examined the association between DM and 
breast cancer-specific mortality, and nine the association with colorectal cancer-specific 
mortality. 
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Table 1. Summary of included trials 
Study Country Study  
quality*
Mean FU
(years)
No. of 
patients
Diagnosis 
DM
Outcome Hazard 
ratio
Redaniel et 
al.18 (2012)
UK 8/9 9.88 82 867 Diagnosis in 
database or 
prescriptions 
of anti-DM 
drugs
Breast cancer 
risk
Unadjusted
Yeh et al.19 
(2012)
USA 9/9 17 18 280 Self-reported - Breast and 
CR cancer 
incidence
Multivariable 
adjusted
- Cancer case 
fatality
van de Poll et 
al.20 (2012)
The Nether-
lands
8/9 NS 10 862 Hospital 
medical 
records
CRC-specif-
ic mortality
Unadjusted
Miao et al.21 
(2012)
Sweden 8/9 NS 25 476 HbA1C-
level 
(>58mmol/
mol)
Breast cancer 
incidence
Unadjusted
Dehal et al.22 
(2012)
USA 7/9 6.8 2278 Self-reported CRC-specif-
ic mortality
Calculated
Dankner et 
al.23 (2012)
Israel 8/9  21.9 1695 Insulin levels Breast and 
CR cancer 
incidence
Adjusted 
for age and 
ethnicity
Liu et al.24 
(2011)
Sweden 7/9 7 16 123 Hospital-
ization for 
T2DM
Cause-specif-
ic mortality
Multivariable 
adjusted
Stefansdot-
tir et al.25 
(2011)
The Nether-
lands
3 
( Jadad)
5.0 11 140 HbA1C-
level > 6.5%
Breast cancer 
incidence
Unadjusted
Seshasai et 
al.26 (2011)
UK - 13.6 820 900 Self-
reported, 
medication 
use, fasting 
glucose level
Breast and 
CR cancer 
death
Multivariable 
adjusted
Morrison et 
al.27 (2011)
UK 7/9  26.3 17 949 Self-report-
ed, blood 
glucose 
levels, IGT
CRC death Age adjusted
Lam et al.28 
(2011)
Asian Pacific 
Region
- 4.0 367 361 Self-report-
ed, (fasting) 
blood glu-
cose levels
Site specific 
cancer mor-
tality
Age adjusted
Irwin et al.29 
(2011)
USA 8/9 6.0 604 C-peptide 
levels > 
1.7nl/mL
Death from 
breast cancer
Age adjusted
Erickson et 
al.30 (2011)
USA 9/9 10.3 3088 HbA1C-
levels >6.5%
Breast cancer 
mortality
Calculated
Duggan et 
al.31 (2011)
USA 7/9 6.4 527 HOMA-
score > 1.04
Breast cancer 
mortality
Unadjusted
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Zhou et al.32  
(2010)
Finland 6/9 15.8 44 655 Glucose 
tolerance 
status
Death from 
breast and 
CR cancer
Calculated
He et al.33 
(2010)
USA 6/9 NS 199 142 Self-reported CRC inci-
dence
Age adjusted
Campbell et 
al.34 (2010)
USA 7/9 12.06 184 194 Self-reported CRC inci-
dence
Calculated
Flood et al.35 
(2010)
USA 6/9 8.4 45 516 Self-reported CRC inci-
dence
Age-adjusted
Ogunleye et 
al.36 (2009)
Scotland 5/9 Diabetics: 
3.9
19 154 Medical 
records
Breast and 
CR cancer 
incidence
Calculated
Non-diabet-
ics: 4.04
van de Poll et 
al.37 (2007)
The Nether-
lands
8/9 NS 58 498 Medical 
records
CRC death Calculated
*Studies scored according to the Newcastle-Ottawa scale and Jadad-criteria.(FU = follow up, DM = diabetes 
mellitus, CR = colorectal, CRC = colorectal cancer, T2DM = type 2 diabetes mellitus, IGT = impaired glucose 
tolerance, HOMA = homeostatic model assessment, NS = not stated)
Effect estimates
There was no heterogeneity among the 12 studies that reported the incidence of DM 
in patients with breast  (I2 = 0 per cent, P = 0.640) and colorectal (I2 =13 per cent, P = 
0.330) cancer. The studies that reported on breast cancer-specific mortality showed low 
heterogeneity (I2 = 30 per cent, P = 0.190). Those reporting colorectal cancer-specific 
mortality showed moderate to high heterogeneity (I2 =59 per cent, P = 0.010).
Primary outcomes
Incidence of breast cancer 
Fig. 2 shows the result of meta-analysis of the six studies that reported on the incidence 
of breast cancer in patients with DM (18,19,21,23,25,36). The random-effects model 
showed an association between the incidence of breast cancer and DM (HR 1.23, 95 per 
cent c.i. 1.12 to 1.34; P < 0.001).
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Figure 2. Meta-analysis of breast cancer incidence for patients with versus those without diabetes mellitus 
(DM). An inverse variance random-effects model was used. Hazard ratios (HRs) are shown with 95 per 
cent confidence intervals. s.e., Standard error.
Incidence of colorectal cancer 
The result of meta-analysis of the six studies that reported on the incidence of colorectal 
cancer in patients with DM is shown in Fig. 3 (19,23,33–36). The random-effects model 
demonstrated an association between colorectal cancer incidence and DM (HR 1.26, 
1.14 to 1.40; P < 0.001).  
Figure 3. Meta-analysis of colorectal cancer incidence for patients with versus those without diabetes 
mellitus (DM). An inverse variance random-effects model was used. Hazard ratios (HRs) are shown with 
95 per cent confidence intervals. s.e., Standard error.
Breast cancer-specific mortality
Fig. 4 shows the result of meta-analysis of the eight studies on breast cancer-specific 
mortality (19,24,26,28–32). The random-effects model showed that patients with DM 
had an increased breast cancer-specific mortality (HR 1.38, 1.20 to 1.58; P < 0.001).
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Figure 4. Meta-analysis of breast cancer-specific mortality for patients with versus those without diabetes 
mellitus (DM). An inverse variance random-effects model was used. Hazard ratios (HRs) are shown with 
95 per cent confidence intervals. s.e., Standard error
Colorectal cancer-specific mortality
Meta-analysis of the nine studies that reported on colorectal cancer-specific mortality, 
using a random-effects model, demonstrated an increased risk of death due to colorectal 
cancer in patients with DM (HR 1.30, 1.15 to 1.47; P < 0.001) (Fig. 5) (19,20,22,24,26–
28,32,37).
Figure 5. Meta-analysis of colorectal cancer-specific mortality for patients with versus those without 
diabetes mellitus (DM). An inverse variance random-effects model was used. Hazard ratios (HRs) are 
shown with 95 per cent confidence intervals. s.e., Standard error
Adjusted HRs
Additional analyses in which multivariable adjusted HRs were pooled did not change 
the results significantly (data not shown), except for a slightly attenuated overall HR for 
breast cancer incidence (HR 1.11, 1.00 to 1.23; P = 0.050).
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Publication bias
For each study, the risk of publication bias was estimated by plotting the log HR against 
the corresponding standard error. In none of the meta-analyses did visual inspection 
of the funnel plots or application of  Egger’s test reveal asymmetry or a statistically 
significant regression intercept, indicating absence of  publication bias (Figs S1–S4, 
supplemental material).
Sensitivity and subgroup analyses
Sensitivity analysis
To assess the influence of individual studies on overall outcome they were removed one 
by one. Removing the study of Redaniel and colleagues (18) decreased the HR for the 
incidence of breast cancer in the meta-analysis to 1.09 (0.93 to 1.28; P = 0.268). In 
meta-analyses of the incidence of colorectal cancer, breast cancer-specific mortality and 
colorectal cancer mortality the I2 value decreased (to 0, 5 and 40 per cent respectively), 
albeit not significantly, by  removing the studies reported by Campbell and colleagues 
(34), Lam and co-workers (28) and van de Poll-Franse et al. (37) respectively. Removing 
these studies did not have a significant impact on the overall HRs (data not shown).
Subgroup analysis of unadjusted and multivariable adjusted hazard ratios
A subgroup analysis was conducted for unadjusted and multivariable adjusted HRs. The 
studies that reported unadjusted HRs for the incidence of breast and colorectal cancer 
had an overall HR of 1.22 (1.11 to 1.34; P < 0.001)(18,21,25,36) and 1.28 (1.13 to 1.46; 
P < 0.001)(33–36) respectively for patients with versus without DM. Analysing adjusted 
HRs in the studies that reported on the incidence of breast and colorectal cancer did not 
alter these results significantly (Table S1, supplemental material). 
The studies that reported adjusted HRs for breast cancer-specific mortality had an overall 
HR of 1.38 (1.23 to 1.55; P < 0.001)(19,24,26,28,29,32). For colorectal cancer-specific 
mortality the unadjusted and adjusted overall HRs remained increased: 1.32 (1.07 to 1.32;  
P = 0.009)(20,22,32,37) and 1.28 (1.07 to 1.53; P = 0.008)(19,24,26–28) respectively. 
Subgroup analysis of mode of assessment of diabetes
A pooled HR was calculated for studies with self-reported or previously diagnosed DM 
and studies that used blood tests to assess DM. In the four meta-analyses the pooled HR 
remained increased for studies in which DM was self-reported (data not shown). When 
the studies that used blood tests to diagnose DM were combined, only the pooled HR for 
breast cancer mortality remained increased (HR 1.54, 1.14 to 2.07; P = 0.004)(29–32).
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Subgroup analysis of follow-up time
This subgroup analysis explored the impact of a mean follow-up of 10 years or less, and 
more than 10 years. The pooled HR for breast cancer incidence and cancer-specific 
mortality in studies with a mean follow-up of 10 years or less was 1.26 (1.14 to 1.39; P 
< 0.001) and 1.30 (1.30 to 1.52; P = 0.001) respectively for patients with versus those 
without DM(18,24,25,28,29,31,36). Studies with follow-up of more than 10 years did 
not show an increased incidence and cancer-specific mortality for breast cancer among 
patients with DM. 
The pooled HR for colorectal cancer incidence remained significantly increased in 
studies with a mean follow-up of 10 years or less (HR 1.49, 1.14 to 1.94; P = 0.003)(35, 
36) and also in studies with follow-up of more than 10 years (HR 1.25, 1.03 to 1.52; P = 
0.030)(19, 23, 24). For colorectal cancer mortality, the pooled HR remained significant 
only for patients with follow-up of more than 10 years (HR 1.24, 1.11 to 1.38; P < 0.001)
(19,26,27,32).
Discussion
This meta-analysis showed that patients with DM have an increased risk for breast and 
colorectal cancer of 23 and 26 per cent respectively. A 38 per cent higher cancer-specific 
mortality in patients with diabetes and breast cancer, and a 30 per cent higher cancer-
specific mortality in patients with diabetes and colorectal cancer, was demonstrated. The 
overall HRs for DM and cancer incidence and mortality were consistent for unadjusted 
and adjusted HRs.  Finally, follow-up of more than 10 years confirmed an increased risk 
of colorectal cancer-specific mortality in patients with DM; for follow-up times of 10 
years or less, there was a positive association between DM and breast cancer incidence 
and mortality, and colorectal cancer incidence. 
The results for breast and colorectal cancer incidence in patients with DM are consistent 
with those of other meta-analyses (38–42). The present meta-analysis showed a higher 
risk and a stronger association between DM and cancer-specific mortality for breast and 
colorectal cancer than reported previously (40,43–45). 
This meta-analysis had several limitations. First, not all included studies distinguished 
between type I and type II DM. The two types are associated with an increased risk 
for different cancers, and the underlying mechanisms promoting carcinogenesis might 
differ (46,47). The inclusion of individuals with type I DM could have led to an 
underestimation of the overall effect on cancer incidence and mortality. Second, the use 
of antidiabetic medication was not taken into account. There is evidence that metformin 
has a protective effect on breast cancer risk and colorectal cancer mortality, and recent 
studies have reported that insulin may increase cancer risk (48–51). Additionally, the 
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risk of cancer varies with the duration of DM and varying use of diabetes medication 
(52), but the study did not account for detection time bias. In this review multivariable 
adjusted HRs were pooled and these results did not differ essentially from those of 
analyses based on unadjusted HRs. The included studies showed no or moderate 
heterogeneity, and there was no evidence of publication bias. By calculating the overall 
outcome on the basis of HRs, the risk of selection bias with respect to the endpoints 
chosen was less than it would have been had relative risks been used (53), because HRs 
represent the instantaneous event rate. 
It is suggested that future cohort studies should adjust for the type of DM (or only 
include individuals with type II DM), the duration of DM and the use of antidiabetic 
medication to further analyse the impact of DM on cancer incidence and mortality.
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Supplemental material
Figure S1. Funnel plot of studies reporting breast cancer incidence
Figure S2. Funnel plot of studies reporting colorectal cancer incidence
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Figure S3. Funnel plot of studies reporting breast cancer-specific mortality
Figure S4. Funnel plot of studies reporting colorectal cancer-specific mortality
Table S1. Results of subgroup analysis of unadjusted and multivariable adjusted hazard ratios 
Overall HR, unadjusted Overall HR, multivariable adjusted
Breast cancer incidence HR 1.22 (95 per cent c.i. 1.11-1.34, 
P <0.001)18,21,25,36 
HR 1.19 (95 per cent c.i.  0.78-1.80,  
P = 0.430)19,23 
CRC incidence HR 1.28 (95 per cent c.i. 1.13-1.46,
 P < 0.001)33-36 
HR 1.14 (95 per cent c.i. 0.68-1.92,  
P = 0.620)19,23 
Breast cancer mortality HR 1.69 (95 per cent c.i. 0.71-4.03, 
P = 0.230)30,31 
HR 1.38 (9% per cent c.i. 1.23-1.55, 
P <0.001)19,24,26,28,29,32
CRC mortality HR 1.32 (95 per cent c.i. 1.07-1.32, 
P = 0.009)20,22,32,37 
HR 1.28 (95 per cent c.i.  1.07-1.53, 
P = 0.008)19,24,26-28
CRC; colorectal cancer, HR; hazard ratio, c.i.; confidence interval
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Abstract
Aim
Type 2 diabetes is associated with an increased cancer risk. Most studies on this topic 
analyse diabetes as a risk factor without adjusting for diabetes duration before cancer 
occurrence. This study aimed to investigate the association between diabetes duration 
and cancer risk in more detail.
Methods
In this prospective cohort study, diabetes diagnosis was based on clinical information and 
use of glucose lowering medication. Details on incident cancers were obtained via general 
practitioners and linkage to pathology registers. Cox proportional hazards models were 
used with onset and duration of diabetes as time-varying determinants.
Results
The study comprised 10,181 individuals. Diabetes was associated with an increased 
overall risk of incident cancers (hazard ratio (HR) 1.2, 95% confidence interval (CI) 
1.07-1.39) and pancreatic cancer (HR 2.9, 95% CI 1.75-4.89). A diagnosis of diabetes 
less than three months before the diagnosis of cancer was associated with strongly 
increased risks of all- (HR 3.3, 95%CI 2.50-4.32) and pancreatic cancers (HR 28.7, 
95%CI 6.32-130.58).  
Conclusions
The magnitude of the association between diabetes and an increased risk of cancer 
seems to be inflated by detection- or protopathic bias. Future studies investigating this 
association should adjust for diabetes duration and include a plausible aetiological risk 
window. 
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Introduction
There is increasing evidence that type 2 diabetes is associated with an increased risk of 
cancer (1). However, risk estimates vary per specific cancer site (2-7) and moreover, with 
regard to prostate cancer, diabetes seems to be a protective factor (8-10). Several possible 
mechanisms have been proposed as an explanation for the association between type 2 
diabetes and the increased cancer risk (11). Obesity is a major acquired risk factor for 
diabetes as well as for cancer (12). Another possible mechanism is via hyperinsulinaemia - 
that exists in both diabetic and obese patients and that stimulates the insulin and insulin-
like growth factor (IGF) axis (11). Furthermore, evidence suggests that certain oral 
glucose-lowering drugs (e.g. metformin) have a protective effect on cancer risk but that 
certain forms of insulin therapy may increase cancer risk (13-16). 
Despite the growing body of evidence on the association between type 2 diabetes and 
an increased risk of cancer, several points should be emphasised. First, the association is 
complex as, for example, age and obesity are risk factors associated with both outcomes 
(1). Thus, it is important that studies should adjust for these potential confounders. 
Second, most observational studies on this topic analyse diabetes as a dichotomous risk 
factor without taking into account the moment of onset or duration of diabetes before 
cancer occurrence (1, 17). In this way, detection bias, to which the increased cancer risk 
has partially been attributed (18-20), cannot be assessed. To account for detection bias, 
duration of diabetes should be studied in more detail, with duration of diabetes divided 
into groups of increasing duration. In this way, impact of diabetes per time window can 
be assessed more accurately.
Finally, carcinogenesis is a slow and multistage process that develops over a period of 
several years (21). The latency and so-called sojourn periods differ per cancer type – and 
sometimes amount to a few decades – (22) thus making it difficult to analyse when 
diabetes has its impact in carcinogenesis. 
We tested the hypothesis that the long-term exposure of diabetes in the elderly is 
associated with an increased risk of some cancers whereas increased risk associated with 
the peri-diagnosis of diabetes reflects biases like detection bias and protopathic bias. 
Therefore, the objective of this study was to investigate the association between diabetes 
duration and cancer risk in detail in order to confirm results with regard to detection bias 
and possibly resolve problems from earlier studies on this topic. 
Patients and methods
Setting
Data were obtained from the Rotterdam Study, a large population-based prospective 
cohort study. The objectives and design were extensively described elsewhere (23, 24). 
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In brief, since 1990, inhabitants of the suburb Ommoord, aged 55 years or older were 
invited to participate. Of all 10,275 invited subjects 7983 entered the study (78%). 
In 2000, a second cohort with 3011 participants (of 4472 invitees, 67%) was added 
(Rotterdam Study II). Cancer cases were registered via the general practitioners, on the 
basis of discharge letters, and by linkage with the academic and regional laboratory for 
clinical pathology through a nationwide registry of histo- and cytopathology in the 
Netherlands (PALGA). The Rotterdam Study has been approved by the Medical Ethics 
Committee and all participants have received written and oral informed consent. 
Definition of diabetes duration
Diabetes mellitus was diagnosed on the basis of a fasting plasma glucose level of ≥7.0 
mmol/L (≥126 mg/dL), or non-fasting plasma glucose levels of ≥11.1 mmol/L (≥200 
mg/dL),  or use of blood glucose lowering medication. Date of onset of diabetes was 
estimated by reference to the date of first prescription of a glucose-lowering drug 
(Anatomical Therapeutical Chemical code (ATC-code) A10 (25)) based on linkage 
with pharmacies that serve the Ommoord district. Duration of diabetes was defined as 
the time interval between the date of onset of diabetes and the date of cancer diagnosis 
in cases and the same follow-up date in the remainder of the non-censored part of the 
cohort. Cohort members were censored on the date of first cancer, death or end of the 
study period, whichever came first. 
Regarding the non-diabetic participants the follow-up period started at the moment 
of inclusion in the study, until the date of first cancer, death or end of the study period, 
whichever came first.
Outcome
The outcomes of interest were all incident cancers combined, further specified into 
separate models for the five most frequently occurring cancer types in the Rotterdam 
Study: breast cancer, prostate cancer, pancreatic cancer, lung cancer and colorectal cancer. 
With regard to the cancer diagnoses, haematological cancers and non-melanoma skin 
cancers (NMSC) were excluded. Cancers were classified according to the International 
Statistical Classification of Diseases and Related Health problems, 10th revision (ICD-
10) (26) and the International Classification of Primary Care, 2nd edition (ICPC-2) (27). 
All cancer cases were confirmed by pathology records. 
Covariables
The following baseline patient characteristics, all determined by baseline interview 
or during the visits to the examination centre, were considered as clinically relevant 
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confounders: age, sex, baseline body mass index (BMI; kg/m2), smoking status (never/
former/current), current alcohol use (yes/no) and year of inclusion in the study. 
Additionally, educational level, income, prevalence of transient ischaemic attacks 
(TIA), myocardial infarction (MI), stroke (CVA), peripheral artery disease (PAD), 
cardiovascular disease (CVD), percutaneous transluminal coronary angioplasty 
(PTCA, yes/no) and coronary bypass (yes/no) were all individually assessed as potential 
confounders. If the variables changed the point estimate by more than 10% they were 
included in the final multivariable model. Ethnicity was not assessed as a confounder 
since 98% of the cohort was Caucasian.
Furthermore, in additional analyses use of glucose-lowering medication at baseline 
(metformin, insulin and SU-derivatives) was taken into account. 
Statistical analysis
For each cohort participant, follow-up was defined in days starting from inclusion in the 
study until date of cancer diagnosis, death, or end of the study period (1st January, 2011), 
whichever came first. For comparison at baseline of normally distributed continuous 
variables, Student’s t-test was used and for categorical variables Chi-square tests were used to 
assess differences between the diabetic and the non-diabetic population. A Cox regression 
analysis was carried out to assess the association between diabetes and cancer incidence with 
onset of diabetes as the time-dependent variable. Subsequently, Cox regression analyses were 
performed with duration of diabetes as a time-dependent determinant. Hereto, diabetes 
duration was divided into three mutually exclusive groups on the basis of duration of diabetes 
on the event date (incident diabetes with duration from 1 to 90 days, 91 days to 5 years, and 
> 5 years, respectively). Furthermore, separate analyses for the different incident cancers were 
performed. Multiple imputations (ten times) were used to assess the effect of missing values. 
P-values were considered significant if p < 0.05. All analyses were performed using SPSS 
software (SPSS Inc., version 21.0, Chicago, Illinois, United States of America (USA)).  
Results
General characteristics
At baseline, 248 patients had a history of cancer and 565 patients had a diabetes diagnosis 
before start of the study. They were excluded, leaving 10,181 study participants of whom 
4087 men (40%) and 6094 women (60%). Median age was 69 years (SD 9.7). Mean follow-
up time was 11 years (SD 5.8 years). The mean BMI of the total cohort was 27 (SD 3.9). 
A total of 906 participants were dispensed glucose-lowering drugs and they were 
considered to have diabetes (9%). In the age category of >65 to <75 years the incidence 
of incident diabetes was the highest (11%, table 1). There were 2238 patients (22%) 
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diagnosed with cancer. Table 1 further describes the general characteristics of the diabetic 
and non-diabetic participants at baseline. Supplementary figure 1 shows the flowchart of 
how many participants developed diabetes and cancer. 
Table 1. General characteristics of the diabetic and non-diabetic participants at baseline.
Non-diabetics Diabetics P-value
Total 9275 (91%) 906 (9%)
Sex Female 5560 (60%) 534 (59%) 0.56
Male 3715 (40%) 372 (41%)
Age 69 (mean) 68 (mean) 0.00
(SD 9.8) (SD 8.2)
Age =>55 - <65 4013 (91%) 390 (9%)
=>65 - <75 2687 (89%) 343 (11%)
=>75 - <85 1816 (93%) 142 (7%)
=>85 - <95 709 (96%) 31 (4%)
=>95 50 (100%) 0 
Follow-up time (years) 11 (mean) 13 (mean) 0.00
(SD 5.8) (SD 5.1)
BMI 26 (mean) 29 (mean) 0.00
(SD 3.8) (SD 4)
Smoking Never 3140 (35%) 303 (34%) 0.75
Former 3804 (43%) 389 (44%)
Current 1983 (22%) 194 (22%)
TIA 94 (1.8%) 11 (1.7%) 0.93
MI 830 (14%) 104 (16%) 0.17
PTCA 52 (0.8%) 2 (0.3%) 0.24
Coronary bypass 134 (2.1%) 25 (3.8%) 0.01
PAD 1032 (19%) 88 (15%) 0.02
CVD 1899 (29%) 205 (30%) 0.48
CVA 202 (3.1%) 22 (3.2%) 0.87
Educational level Low 5081 (55%) 527 (59%) 0.22
 Middle/ High 3777 (41%) 344 (38%)
Income Low 3796 (50%) 428 (55%) 0.02
 High 3733 (50%) 354 (45%)
Cancer diagnosis Yes 2086 (22%) 152 (17%) 0.00
 No 7189 (78%) 754 (83%)
SD, standard deviation; BMI, body mass index; TIA, transient ischaemic attacks; MI, myocardial infarction; 
PTCA, percutaneous transluminal coronary angioplasty; PAD, peripheral artery disease; CVD, cardiovascular 
disease; CVA, cerebrovascular accident. Bold values indicate statistically significant results.
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Risk of cancer in diabetic participants
The results of the univariable time-dependent Cox regression analyses are shown in table 
2. Diabetes was associated with a statistically significantly elevated hazard ratio (HR) 
for all cancers, as well as for breast- and pancreatic cancer. In contrast, diabetes was 
associated with a decreased risk of prostate cancer albeit statistically non-significant. The 
results of the multivariable time-dependent Cox regression are also shown in table 2. No 
variable proved to be a statistically relevant confounder that changed the point estimate 
by more than 10%; therefore no additional variables were added to these multivariable 
models next to clinically relevant confounders as described in the methods section. HRs 
remained elevated for all cancers and for pancreatic cancer. Further adjustment for use 
of glucose-lowering medication at baseline (metformin, insulin and SU-derivatives) 
mainly altered the risks of cancer, especially when adjusted for use of  metformin and SU-
derivatives (supplementary table 1). However, numbers of cancer cases were small in these 
analyses, so accuracy of these results can be questioned.
Table 2. Uni- and multivariable time-dependent analysis.
Cancer type Cases non-DM Cases DM Univariable analysis Multivariable analysis
HR HR
All cancer 2086 152 1.3 1.2
(95%CI 1.01-1.53) (95%CI 1.09-1.53)
Breast cancer 2271 21 1.7*† 1.5*†
(95%CI 1.08-2.65) (95%CI 0.97-2.44)
Prostate cancer 329 12 0.6† 0.7†
(95%CI 0.36-1.15) (95%CI 0.37-1.18)
Pancreatic cancer 69 15 3.4 3.6
(95%CI 1.93-6.02) (95%CI 1.98-6.41)
Lung cancer 284 20 1.2 1.3
(95%CI 0.73-1.82) (95%CI 0.82-2.08)
Colon cancer 156 10 1.0 1.0
(95%CI 0.54-1.97) (95%CI 0.57-2.10)
Rectal cancer 67 7 1.9 2.0
(95%CI 0.89-4.08) (95%CI 0.90-4.50)
Rectosigmoid cancer 89 5 1.1 1.1
(95%CI 0.42-2.61) (95%CI 0.43-2.72)
Univariable analysis adjusted for age and sex. 
Multivariable analysis adjusted for age, sex, BMI, smoking status, alcohol use and year of inclusion in the study. 
Bold values indicate statistically significant associations.
*Analysis in women only, 
† Not adjusted for sex
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Analyses accounting for diabetes duration
The results from the additional model in which diabetes duration was divided into three 
groups are shown in figure 1. Within three months of a diabetes diagnosis the HR for all 
cancers was 3.3 (95% confidence interval (CI) 2.50-4.32) and for pancreatic cancer 28.7 
(95%CI 6.32-130.58). The risk of all cancers remained statistically significantly increased 
among diabetic patients when diabetes duration was between three months and five years 
(HR 1.4, 95%CI 1.11-1.71) but not when the diabetes duration was more than five years 
(HR 1.1, 95%CI 0.92-1.41). Regarding pancreatic cancer the risk remained elevated 
when diabetes duration was between three months and five years, albeit non-significantly 
(HR 2.3, 95%CI 0.63-8.30). For a diabetes duration of more than five years no increased 
risk of pancreatic cancer could be found (HR 1.0, 95%CI 0.29-3.15). The risk of breast 
cancer was borderline statistically significantly decreased for a duration of diabetes of 
more than five years (HR 0.6, 95%CI 0.39-0.99) but not for a diabetes duration between 
three months and five years (HR 1.1, 95%CI 0.64-1.70). 
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Figure 1: multivariable model of duration of diabetes exposure. Adjusted for age, sex, BMI, smoking 
status, alcohol use and year of inclusion in the study. Prostate and breast cancer not adjusted for sex, breast 
cancer analysis in women only. *Indicates statistically significant result.
statistically significant result.
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Discussion
In this prospective population-based follow-up study, we hypothesised that there would 
be an increased risk of cancer among people with diabetes but that this risk would vary 
by duration of diabetes. The incidence of diabetes was 9%, which is similar to the rate of 
diabetes in another Dutch study on diabetes and cancer (28). Overall, the risk of cancer 
was increased by 20% among participants with diabetes. Duration of diabetes of less than 
three months before a cancer diagnosis was associated with a threefold increased risk of 
all cancer while a diabetes duration between three months and five years was associated 
with a much lower increased risk of all cancers of 40%. This high risk shortly after starting 
glucose-lowering drugs is probably explained by detection bias or protopathic bias. 
Diabetes was associated with a more than threefold increased risk of pancreatic cancer 
but this was mainly explained by a peak within 3 months before diagnosis and probably 
also a result of detection bias because after longer durations of diabetes, the risk of 
pancreatic cancer declined and rendered statistically not significant. 
Earlier literature showed increased overall cancer risks varying from 14% to 56% (19, 
29-31). However, not all of these studies investigated diabetes duration extensively. 
Regarding breast cancer, earlier studies also described conflicting results. A study from 
2011 (18) found a non-significant trend towards an increased breast cancer risk within 
three months of diabetes diagnosis which might be caused by detection or protopathic 
bias. In another study, no increased risk of breast cancer was found (19). However, both 
studies did not adjust for BMI which is important as shown earlier (12).
Concerning pancreatic cancer, our results are conflicting with two studies investigating 
diabetes duration and pancreatic cancer that found significantly elevated risks with longer 
durations of diabetes (32, 33). Another study also found a decrease towards a protective 
effect in pancreatic cancer risk by increasing duration of type 2 diabetes (19). However, 
only one adjusted for BMI (33).
Regarding the protective effect that diabetes appears to have on prostate cancer, our study 
only showed a trend toward this phenomenon. Other studies on prostate cancer and 
diabetes reported a decreased risk by increasing duration of diabetes (19, 34), whereas in 
our study the risk increased (albeit non-significantly).
The protective effect seen in breast cancer after a diabetes diagnosis of more than five 
years is unexpected. We hypothesise that a possible explanation for this phenomenon 
might be that some tumors are not sensitive to insulin and thus will not experience IR 
and IGF-R up regulation. Thus, the PI3K-, MAPK- and mTOR-pathways will not be 
activated and carcinogenesis will not be stimulated, no matter what period of time.
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Strengths and limitations
Strengths of this study are the large number of patients, the long follow-up period and 
its prospective design. Furthermore, this study was able to adjust for the most important 
confounders and thus aimed to examine diabetes as an independent risk factor for cancer. 
Also, effects of use of glucose-lowering drugs at baseline were assessed; however results of 
these analyses need to be interpreted with caution due to small numbers of cancer cases. 
The time-dependent analyses with adjustment for diabetes duration further increase the 
strength of the results. A limitation of this study is that no distinction could be made 
between type 1 and type 2 diabetes. However, only participants aged 55 years or older 
were included, so it can be assumed that in participants with incident diabetes, everyone 
was of type 2. Additionally, because of the 70%-response rate in the Rotterdam Study, the 
possibility exists that diabetes is underreported if the non-responders tend to be diabetic 
more often. Alas, information about these non-responders is unknown. Furthermore, 
the time-dependent analysis also revealed potential detection- or protopathic bias 
because a diagnosis of incident diabetes made during the three-month period before the 
cancer diagnosis date was associated with an increased hazard ratio for cancer of even 
3.3.  Lastly, a latency or a so-called sojourn period is important. As mentioned in the 
introduction, these time periods differ per cancer type, making it difficult to determine 
a correct aetiological risk window to analyse when diabetes has its possible impact on 
carcinogenesis.
In conclusion, this study showed that risk of cancer varies with the duration of diabetes. 
The magnitude of the association between diabetes and increased risk of cancer seems to 
be inflated by detection- or protopathic bias. Future studies investigating this association 
should take into account the duration of diabetes and a plausible etiological risk window. 
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Supplemental material
Supplementary figure 1. Flowchart of how many participants developed diabetes and cancer.
10.181 participants 
9275 
non-diabetics 
906 
diabetics 
2086 
cancer cases 
152  
cancer cases 
271 breast cancer 
329 prostate cancer 
69 pancreatic cancer 
284 lung cancer 
156 colon cancer 
67 rectal cancer 
89 rectosigmoid cancer 
21 breast cancer 
12 prostate cancer 
15 pancreatic cancer 
20 lung cancer 
10 colon cancer 
7 rectal cancer 
5 rectosigmoid cancer 
    14.747  
     invitees 
3.753 non- responders 
248 cancer history 
565 prevalent diabetics 
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Supplementary table 1. Multivariable time-dependent analysis. 
Cancer type Cancer Adjusted for  Cancer Adjusted for SU Cancer Adjusted for  
cases Metformin cases cases Insulin
(n = 304) (n = 544) (n = 45)
HR HR HR
All cancer 277 1.5 116 2.0 8 1.3
(95%CI 1.24-1.74) (95%CI 1.64-2.54) (95%CI 1.12-1.57)
Breast cancer 5 1.8*† 16 2.4*† 0 1.6*†
(95%CI 1.12-2.79) (95%CI 1.35-4.39) (95%CI 1.02-2.56)
Prostate 1 0.8† 11 1.1† 0 0.7†
cancer (95%CI 0.42-1.36) (95%CI 0.54-2.27) (95%CI 0.39-1.24)
Pancreatic 3 3.9 11 4.3 1 3.5
cancer (95%CI 2.13-7.16) (95%CI 1.83-10.24) (95%CI 1.93-6.39)
Lung cancer 3 1.5 13 2.2 4 1.2
(95%CI 0.96-2.45) (95%CI 1.24-4.02) (95%CI 0.74-1.95)
Colon cancer 0 1.4 10 1.2 0 1.2
(95%CI 0.70-2.59) (95%CI 0.48-2.85) (95%CI 0.60-2.22)
Rectal cancer 1 2.3 6 2.1 0 2.1
(95%CI 1.02-5.21) (95%CI 0.68-6.54) (95%CI 0.93-4.70)
Rectosigmoid 1 1.2 4 1.9 0 1.2
cancer (95%CI 0.48-3.07) (95%CI 0.58-6.05) (95%CI 0.46-2.89)
Adjusted for age, sex, BMI, smoking status, alcohol use and year of inclusion in the study. Prostate and breast 
cancer not adjusted for sex, breast cancer analysis in women only. Further adjusted for baseline use of metformin, 
SU-derivatives or insulin. Bold values indicate statistically significant associations.
*Analysis in women only
† Not adjusted for sex
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Abstract
Background and Objectives 
Esophageal adenocarcinoma (EAC) incidence increases, maybe due to increasing 
prevalences of obesity and diabetes. Concurrent hyperinsulinemia might promote 
carcinogenesis via the insulin-like growth factor-I –receptor (IGF-1R). Expression of the 
IGF-1R was studied in correlation with diabetes and prognostic parameters.
Methods 
Patients with EAC undergoing esophagectomy were prospectively selected. From 
resected tumors a tissue microarray was constructed. Immunohistochemistry evaluated 
IGF-1R-expression. Logistic-, cox regression models and survival analyses assessed if 
diabetes and IGF-1R-expression were associated with prognostic parameters. IGF-1R-
expression in normal and Barrett tissues was studied.
Results 
Absence or low IGF-1R-expression was associated with T3-, grade 3 tumors and R1 
resections (P= 0.001, P=0.025, P < 0.001, respectively). Logistic regression showed 
that this was associated with R1 resections (HR 0.24, 95%CI 0.11-0.52). Diabetes was 
not associated with IGF-1R-expression (P=0.612). Absence or low IGF-1R-expression 
decreased five-year overall survival (P= 0.023) univariably, but not multivariably. IGF-
1R-expression was present in Barrett tissues, but diminished in high-grade dysplasia.
Conclusions 
Absence or low expression of IGF-1R was associated with high grade- and advanced 
tumors and less radical resections. IGF-1R might be a tumor marker in Barrett’s 
esophagus since a change in expression patterns was found in the course from normal 
esophageal tissue to adenocarcinoma.  
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Introduction
In 2012, the estimated overall number of new incident esophageal cancer cases was 
456.000, thereby being the eight most common cancer worldwide. It was the sixth most 
common cause of death from cancer with 400.000 deaths annually (1). Over the past 
decades the incidence of esophageal adenocarcinoma (EAC) has increased in Western 
countries, while the incidence of esophageal squamous cell carcinoma (ESCC) remains 
stable or even decreases (2). An explanation for this shift in incidences might be the 
increasing prevalence of obesity in the Western world (3). Overweight and obesity are 
strongly associated with an increased risk of EAC (4,5). Additionally, as a result of the 
increasingly obese population, the prevalence of diabetes mellitus (DM) rises as well (6). 
In the past years, obesity and DM have been associated with an increased risk of several 
cancers and higher cancer mortality (3,7-11). Obesity is thought to increase cancer risk 
because of the endocrine function of adipose tissue and its release of peptide hormones 
and sex-steroid metabolizing enzymes. The hyperinsulinemia present in obese patients is 
also held responsible (3). In DM, hyperinsulinemia is also thought to increase cancer risk 
(12). 
Thus, both obesity and DM are associated with increased insulin levels that are thought 
to promote carcinogenesis via the upregulation of the insulin-like growth factor-I (IGF-
1R) and the insulin receptor (IR) (12). Both receptors possess tyrosine kinase activity and 
exert their effects via the (PI3K)/AKT-, MAPK- and mTOR-pathways which can result 
in enhanced cell proliferation and reduced apoptosis (12). Overexpression of IGF-1R 
has been reported in several solid tumors, like breast, bladder and colon cancer, although 
with conflicting results, so the clinical and prognostic significance of the overexpression 
remains unclear (13,14).
Regarding EAC less is known about IGF-1R expression and its relation to carcinogenesis 
and prognosis. Also, the link between DM and esophageal carcinoma is not as clearly 
established as it is for some other cancers. Studies report conflicting results varying from 
an increased risk for EAC among diabetics to no increased risk at all (15-18). 
Thus, this study assessed the expression of IGF-1R in EAC. Secondly, IGF-1R-
expression was correlated with DM, prognostic parameters and survival. Additionally, 
normal esophageal tissues and (dysplastic) Barrett tissues were studied, hypothesizing 
that expression patterns change with malignant transformation. In this way IGF-1R 
was studied as a potential tumor marker and predictive tool for patients with Barrett’s 
esophagus. 
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Materials and Methods
Patient selection
All patients were treated at the Department of Surgery of the Erasmus MC University 
Medical Center in Rotterdam, The Netherlands. All patients with EAC who underwent 
potentially curative resection between January 1995 and December 2005 were identified 
from a prospectively maintained institutional database. Complete data on tumor grade, 
clinical- and pathological staging, (neo)adjuvant treatment, patients’ demographics 
and comorbidities were registered. Body mass index (BMI), presence of DM and other 
comorbidities were retrospectively confirmed via review of medical records since these 
were not routinely recorded in the database. The TNM and grading classification 
according to the UICC (Union Internationale Contre le Cancer, 2009, 7th edition) was 
used to assess pathological tumor stage and tumor grade. Radicality was defined as 
R0- and R1-resections, with an R0-resection having a resection margin >1mm (radical 
resection) and an R1 resection having a resection margin =< 1mm (no radical resection).
In addition, 28 samples from 20 patients (who underwent endoscopic mucosal resection 
(EMR)) or esophagectomy between January 2008 and January 2014) containing normal 
esophageal tissue, non-dysplastic or dysplastic Barrett mucosa were studied. Apart 
from EMR and in some cases esophagectomy, these patients did not receive any other 
treatment. 
Medical ethical approval was obtained for the study. 
Tissue microarray
A tissue microarray was constructed. Formalin-fixed, paraffin-embedded tumor blocks 
were obtained from the Department of Pathology at the Erasmus University Medical 
Center in Rotterdam, The Netherlands. For each patient, up to six tumor cores (Ø 1 mm 
each) were taken from the original blocks. Furthermore, an effort was made to include 
multiple sides of the original tumor, including central parts of the tumor and tumor tissue 
at the invasive front. 
Immunohistochemistry
The TMA slides were deparaffinized, rehydrated and antigen retrieval was carried out 
by boiling in Tris-EDTA buffer, pH 9.0. After a blocking step with H2O2, slides were 
incubated with a primary mouse monoclonal antibody against IGF-1R. Visualization 
of the bound antibodies was done with the Dako REALTM EnVisionTM Detection 
System, Peroxidase/DAB+, Rabbit/Mouse (Dako, Agilent Technologies Inc, Glostrup, 
Denmark). Slides were counterstained with hematoxylin and coverslipped. Normal 
human pancreas was used as the positive control and in the negative control the antibody 
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against IGF-1R was omitted. A photo of the positive control can be found in figure 1.
A pathologist specialized on GI pathology (KBI) scored the immunohistochemically 
stained slides, blinded from the clinical data. Thereby, the staining was scored as ‘absent 
or low expression’ or ‘high expression’. ‘High expression’ was defined as intense staining 
in at least 10% of the cells of interest (dysplastic or carcinoma cells), as used in an earlier 
study on IGF-1R expression (19). Membranous or cytoplasmatic localization of the IGF-
1R was also scored. The normal esophageal tissues, non-dysplastic and the low- and high 
grade dysplastic Barrett tissues that were used for comparison of IGF-1R expression went 
through the same staining and scoring process. 
Statistical analysis
Only patients with at least 50% useful cores were included in the analyses in order to 
ensure more reliable measurements. A core was not useful if it did not contain tumor 
tissue or when large artefacts were present. A mean value of the scores of the used cores 
was calculated to obtain one overall value per patient for the IGF-1R-expression. These 
mean values were subdivided into absent or low and high expression (e.g. when 3 out of 5 
cores were positive the mean value was expressed as ‘high expression’ and when 3 out of 5 
cores were negative the mean value was expressed as ‘absent or low expression’). 
The student’s T-test was used for comparison of continuous baseline variables, while the 
Chi-square test was used for categorical variables. Fisher’s Exact test was used when cells 
in crosstabulations contained less than 5 observations. 
Multilevel logistic regression, in the form of a generalized linear mixed model, was used 
in order to account for multiple and varying numbers of measurements per patient (20). 
Thus, in these analyses patients with less than 50% of their cores usable were included. 
Correlations between repeated measurements were accounted for by including a patient 
specific random intercept in the models. Variables that were considered as clinically 
relevant confounders were first analyzed in a univariable analysis. These were age, 
sex, BMI, DM, neoadjuvant therapy, grading, T-stage, N-stage and insulin use. These 
predictors were subsequently included in a multivariable model when their P-values were 
< 0.20.  Finally, predictors with a P-value < 0.05 were fitted in a  multivariable model. 
Age and sex were always included regardless of their significance level. With regard to 
T-stage, T3 and T4 were taken together because of small numbers of T4. 
Cox regression was used to assess the influence of DM, IGF-expression on the five-year 
overall and disease free survival. Independent variables were entered into the equation in 
one step, according to the Enter method. Finally, Kaplan Meier analyses were performed 
and by means of the log-rank test possible differences in five-year overall and disease 
free survival were evaluated. All statistical tests were 2-sided and P-values < 0.05 were 
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considered statistically significant. Statistical analyses were performed with SPSS version 
20.0 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. 
Armonk, NY: IBM Corp.) and SAS version 9.3, TSM1M1. 
Results
Baseline characteristics
The cohort comprised a total of 348 patients. At the time of this analysis, median follow-
up was 90.7 months (range 36.3 –199.7 months). Baseline characteristics are shown in 
table 1. 
After exclusion of patients with less than 50% of their tissue cores useful, 270 patients 
remained for the final analyses. Of these patients, 47% (127 of 270 patients) had a mean 
high expression of IGF-1R, as described in the methods section. A total of 25 patients 
had 100% of their cores positive and 23 patients had 100% of their cores negative. 
Differences between the patients with mean absent or low and high expression of IGF-1R 
are shown in table 1. 
Cytoplasmatic as well as membranous localization of the IGF-1R appeared to occur in all 
scored cores; therefore no further analyses based on localization were performed.
Information on DM was lacking for two patients. The remaining diabetic and non-
diabetic patients in this cohort did not differ in baseline characteristics, except for BMI, 
which was higher in the diabetic population (mean BMI 26.8 (SD 3.4) vs. 29.6 (SD 3.9), 
P < 0.001), and cardiovascular diseases (CVD), that occurred more frequently in diabetic 
patients (12.7% vs. 31.6%, P=0.037). 
Table 1. Baseline characteristics.
Total population <50% cores useful No or low IGF-1R High IGF-1R P-value
Total 348 78
Sex male 302 (87%) 70 (90%) 123 (86%) 112 (88%)
 female 46 (13%) 8 (10%) 20 (14%) 15 (12%) 0.595
Age (mean) 63.4 (SD 10.3) 62 (SD 9.4) 62.8 (SD 11.0) 64.8 (SD 9.9) 0.121
Dead yes 266 (76%) 46 (59%) 119 (83%) 101 (80%)
 no 82 (24%) 32 (41%) 24 (17%) 26 (21%) 0.436
BMI (mean) 27.2 (SD 3.6) 27 (SD 3.2) 27.5 (SD 3.7) 27 (SD 3.6) 0.340
DM (2 missing) 38 (11%) 10 (13%) 16 (11%) 12 (9%) 0.612
CVD 51 (15%) 9 (12%) 22 (15%) 20 (16%) 0.565
Pulmonary disease 40 (12%) 8 (10%) 10 (7%) 22 (17%) 0.032
CVA/TIA 20 (6%) 3 (4%) 8 (6%) 9 (7%) 0.877
Hypertension 81 (23%) 17 (22%) 35 (25%) 29 (23%) 0.949
Smoking 80 (23%) 21 (27%) 29 (20%) 30 (24%) 0.797
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Neoadjuvant therapy 72 (21%) 38 (49%) 21 (15%) 13 (10%) 0.271
Chemotherapy 70 (20%) 37 (47%) 20 (14%) 13 (10%) 0.348
Radiotherapy 33 (10%) 25 (32%) 7 (5%) 1 (1%) 0.070
Adjuvant therapy 5 (1%) 0 3 (2%) 2 (2%) 1.000
Pathological T-stage 0 9 (3%) 8 (10%) 0 1 (1%)
 1 49 (14%) 24 (31%) 10 (7%) 15 (12%)
 2 61 (18%) 17 (22%) 15 (11%) 29 (23%)
 3 227 (65%) 29 (37%) 117 (82%) 81 (64%)
 4 2 (1%) 0 1 (1%) 1 (1%) 0.017
N-stage (8 missing) 0 146 (42%) 48 (62%) 48 (34%) 50 (41%)
 1 73 (21%) 17 (22%) 31 (22%) 25 (21%)
 2 68 (20%) 8 (10%) 33 (24%) 27 (22%)
 3 53 (15%) 5 (6%) 28 (20%) 20 (16%) 0.709
Tumor location upper 1/3 3 (1%) 1 (1%) 2 (1%) 0
 middle 1/3 19 (6%) 8 (10%) 5 (4%) 6 (5%)
 lower 1/3 130 (37%) 29 (37%) 55 (39%) 46 (36%)
 GEJ 196 (56%) 40 (51%) 81 (57%) 75 (59%) 0.535
IGF-R (mean) (n=270) Abs/low 143 (53%) - - -
 high 127 (47%) - - - -
Grading 1 20 (6%) 11 (14%) 3 (2%) 6 (5%)
 2 143 (41%) 34 (44%) 52 (36%) 60 (47%)
 3 176 (51%) 29 (37%) 87 (61%) 60 (47%) 0.133
Radicality RO 251 (72%) 69 (89%) 81 (57%) 101 (80%)
 R1 97 (28%) 9 (12%) 62 (43%) 26 (21%) 0.000
BMI: body mass index, DM: diabetes mellitus, CVD: cardiovascular disease, CVA: cerebrovascular accident, 
TIA: transient ischemic attack, GEJ: gastro-esophageal junction. Abs: absent. P-values indicate difference between 
groups with absent or low or high IGF-1R expression. Bold numbers indicate statistically significant results.
Receptor expression; patient and tumor characteristics
Diabetes
The presence of DM was not significantly associated with T-stage, N-stage, radicality, 
grading and expression of IGF-1R (data not shown).
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IGF-1R-expression
High expression of IGF-1R was associated with T2 tumors (P=0.006) and R0 resections 
(P < 0.001). Absence or low expression of IGF-1R was associated with T3 tumors, R1 
resections and grade 3 tumors (P=0.001, P < 0.001 and P=0.025 respectively). An 
example of clear and absent expression is shown in figure 1.
Figure 1. Difference in expression pattern in a T2 and T3 tumor. T2-tumor shows clear expression of IGF-
1R, whereas in the T3-tumor IGF-1R expression is absent. Hematoxylin staining, magnification 100x. 
The third photo shows the positive control of normal pancreatic tissue.
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Table 2 shows the results of the generalized linear mixed model (n=338), which showed 
that radicality was the only significant factor associated with IGF-1R-expression. 
Table 2. Generalized linear mixed model for IGF-1R-expression (n=338). 
Univariable analysis First multivariable model Final multivariable model
OR (95%CI) OR (95%CI) OR (95%CI)
Age 1.02 (0.98-1.05) 1.02 (0.98-1.05)  1.02 (0.99-1.05)
Sex 1.36 (0.48-3.89) 1.20 (0.43-3.34) 1.09 (0.39-3.05)
BMI 0.95 (0.86-1.06) *
DM 0.46 (0.15-1.46)  0.53 (0.18-1.62) **
Neoadjuvant 0.56 (0.22-1.43) *
pT 1 Reference category Reference category **
 2 1.77 (0.48-6.54) 2.03 (0.06-7.47)
 3/4 0.38 (0.13-1.15) 0.64 (0.20-2.07)
pN 0 Reference category *
 1 0.71 (0.28-1.82)
 2 0.53 (0.21-1.37)
 3 0.57 (0.21-1.54)
Grading 1 Reference category Reference category **
 2 0.43 (0.10-2.80) 0.63 (0.10-4.02)
 3 0.20 (0.03-1.30) 0.40 (0.06-2.62)
Radical resection yes 0.24 (0.11-0.52) 0.41 (0.18-0.96)  0.24 (0.11-0.52)
Insulin use 2.21 (0.33-14.89) *
DM = diabetes mellitus, NA = not applicable *P-value not under 0.200 in univariable analysis. 
*P-value not under 0.05 in the first multivariable model. Bold numbers indicate statistically significant results. 
Survival
Disease free survival
Survival curves showed that the one-year disease free survival was 59% among the 
patients with absent or low IGF-1R expression and 69% among the patients with high 
IGF-1R expression. IGF-1R expression was not significantly associated with five-year 
disease free survival; only a trend towards a decreased disease free survival among patients 
with absent or low IGF-1R expression was seen (P=0.108, figure 2). The life table can be 
found in supplemental table 1.
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Figure 2. Survival curves of the five-year disease free survival regarding IGF-1R expression (n=270).
The univariable cox regression model with age, sex and DM showed that DM was not 
associated with five-year disease free survival (HR 0.89, P=0.641, 95%CI 0.56-1.43). The 
multivariable model showed that DM, adjuvant therapy, pN2 and pN3 were significantly 
associated with decreased disease free survival (Table 3). 
Overall survival
Survival curves showed that the one-year overall survival was 60% for patients with absent 
or low IGF-1R expression and 75% for patients with high IGF-1R expression. The absence 
or low expression of IGF-1R  was significantly associated with a decreased five-year overall 
survival (P=0.023, figure 3). The life table can be found in supplemental table 2.
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Figure 3. Survival curves of the five-year overall survival regarding IGF-1R expression (n=270).
The model with age, sex and DM showed that DM did not have a significant effect on 
the five-year overall survival (HR 1.01, P=0.684, 95%CI 0.73-1.61). In the multivariable 
model age, pT3/pT4 and pN3 were significantly associated with a decreased five-year 
overall survival (Table 3).
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Table 3. Results of the multivariable cox regression for disease free (DFS) and overall survival (OS). 
Five-year DFS Five-year OS
HR (95%CI) HR (95%CI)
Sex  1.43 (0.85-2.42) 1.07 (0.65-1.75)
Age  1.02 (1.00-1.04)  1.03 (1.01-1.05) 
BMI  1.03 (0.98-1.09) 1.01 (0.96-1.06)
DM 0.51 (0.26-0.99) 0.65 (0.37-1.16)
CVD 1.15 (0.62-2.14) 1.30 (0.77-2.20)
PD 0.81 (0.55-1.18) 1.04 (0.73-1.47)
Smoking 1.23 (0.84-1.80)  0.96 (0.68-1.36)
Neoadjuvant therapy  0.76 (0.44-1.32) 0.71 (0.43-1.16)
Adjuvant therapy 3.82 (1.22-11.89) 2.22 (0.74-6.66)
Grading 1
 2
 3
Reference category
2.08 (0.47-9.14)
3.06 (0.70-13.36)
Reference category
1.26 (0.37-4.27)
1.95 (0.58-6.53)
T-stage 1 
 2
 3/4
Reference category
0.91 (0.31-2.69)
2.48 (0.94-6.57)
Reference category
1.28 (0.49-3.38)
3.12 (1.29-7.53)
N-stage 0
 1
 2
 3
Reference category
 1.67 (0.93-3.00)
1.88 (1.07-3.32)
2.81 (1.54-5.13)
Reference category
1.37 (0.82-2.28)
1.55 (0.95-2.55)
2.27 (1.35-3.83)
Radical resection yes 1.12 (0.72-1.69) 1.19 (0.81-1.74)
IGF-1R expression  0.81 (0.55-1.20) 0.80 (0.56-1.13)
CVD= cardiovascular disease, PD= pulmonary disease. Bold numbers indicate 
statistically significant results. All variables in the table were included in the model. 
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Normal esophageal tissue, Barrett and dysplastic tissue 
To study a possible change in the expression pattern of IGF-1R from normal esophageal 
tissue to invasive adenocarcinoma, 28 additional tissue slides containing normal, non-
dysplastic and dysplastic Barrett tissue were studied. In the 11 slides that contained 
normal squamous esophageal epithelium no IGF-1R expression was found. In the 23 
slides that contained non-dysplastic Barrett tissue in all a strong expression was seen. In 
11 high-grade dysplastic tissues IGF-1R expression became negative (figure 4), where in 
one high-grade dysplastic sample a mixed expression was seen.
Figure 4. Changing expression pattern of IGF-1R expression in resected esophageal tissue. Evident 
expression in non-dysplastic Barrett tissue, diminished expression in high-grade dysplasia. Hematoxylin 
staining, magnification 400x. 
Discussion
The present study described that 47% of the EAC tumors had high expression of the 
IGF-1R. Other studies regarding expression of IGF-1R report percentages varying from 
52% - 82% (21-24). However, two of these studies also included ESCC and did not 
describe EAC separately (22,23). 
Furthermore, in the present study high IGF-1R expression was associated with R0 
resections and T2 tumors whereas absent or low IGF-1R expression was associated with 
T3 and grade 3 tumors and R1-resections. In Kaplan Meier analyses, absent or low IGF-
1R-expression in EAC tumors was associated with decreased five-year overall survival, 
but in multivariable analysis this difference could no longer be seen. 
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These results are partially in conflict with the results from earlier studies. One study 
found no association between IGF-1R expression in EAC and tumor stage and 
survival (25). A study from 2011 (21) found no significant differences between IGF-
1R expression and invasion, tumor stage and tumor differentiation. Results regarding 
disease-specific survival remained inconclusive. A third study (22) described that IGF-1R 
expression was a predictor of poor prognostic outcome in EAC. IGF-1R overexpression 
showed to be associated with invasion depth and overall survival. The explanation for 
these conflicting results might be the high proportion (65%) of T3 tumors in the present 
study. Not all of the studies above described the distribution of T-stage (22) and if 
T-stage was described, percentages and numbers of T3 tumors were (much) lower (58%, 
n = 128 and 38%, n = 36, respectively) (21,25). Furthermore, the fact that in the present 
study IGF-1R-expression was significantly different with respect to overall survival but 
not with disease-free survival might be explained by the five-year time span that was 
taken; this might be too long to detect significant differences with regard to disease-free 
survival since recurrence mostly presents earlier. However, significant results regarding 
overall survival were no longer present in multivariable cox regression. 
Our study is not unique in finding lower expression levels at advanced tumor stages: in 
breast and colorectal cancer this phenomenon has also been described (19,26,27). Also, 
the decrease in expression might be due to the dedifferentiation process to which cancer 
cells are exposed; by becoming more invasive the expression of the IGF-1R gets lost (27). 
On the other hand, IGF-1 is a differentiation factor. Thus, the loss of IGF-1R may be 
responsible for the observed appearance of more primitive and invasive tumors. This is 
in accordance with the decreased prognosis in patients with negative receptor expression 
found in the present study. 
This study found clear expression of IGF-1R in non-dysplastic Barrett tissue, which 
became negative in high grade dysplastic Barrett tissues. This might indicate that IGF-
1R is involved in the malignant transformation of Barrett’s esophagus or as discussed 
above, that loss of the expression of the IGF-1R blocks further differentiation of 
the Barrett cells. Another study investigating the expression of IGF-1R during the 
progression of Barrett’s associated neoplasia showed contradictory results (24); in the 
course from Barrett’s esophagus to EAC, increasing expression of IGF-1R was found. 
One explanation could be that in the present study the tumors were not proven to arise 
in Barrett’s esophagus and most tumors were advanced (65% was staged T3). In the 
study of Iravani et al (24) all tumors developed in Barrett’s-associated neoplasia and the 
percentage of T3 tumors was low (35%). Another explanation for the difference could be 
that the percentages given in the study of Iravani are based on the intensity of the staining 
and not on absence or presence of IGF-1R expression. Nevertheless, further studies are 
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needed to investigate the expression of IGF-1R in the course from Barrett’s esophagus to 
high-grade dysplasia.
Several factors have already been studied as prognostic markers for neoplastic progression 
in Barrett (28) and for survival in EAC. A meta-analysis found that COX-2, HER-2 
and p53 appeared promising markers for the prediction of overall survival in EAC. 
Overexpression of COX-2 and HER-2 were associated with decreased survival, where 
expression of p53 was associated with a better prognosis because of its tumor suppressor 
function (29). Another study provided a biomarker panel consisting of EGFR, TRIM44 
and SIRT2 that was correlated with overall survival in patients with EAC (30).
The present study could stimulate further research on the IGF-1R being an additional 
marker for neoplastic progression in Barrett’s esophagus and for survival in EAC. If the 
IGF-1R could ultimately be established as a marker, patients with expression of IGF-1R 
might then benefit from IGF-inhibiting therapies.
In this study only EACs and not ESCCs were investigated; it has been described that 
expression of IGF-1R is different in EAC than in ESCC (31). Probably in ESCC 
a different molecular pathway may be responsible for carcinogenesis. Furthermore, 
information on tumor stage, tumor grade and radicality was complete for almost every 
patient. Limitations of this study should be addressed. First, this study only included 
patients that were selected for surgery in a tertiairy referral center, thus a selection bias 
could have been present. Second, patients with esophageal cancer frequently suffer from 
severe weight loss and might find themselves in a catabolic state pre- and peroperatively.  
It is known that generalized malnutrition or protein depletion reduces tissue IGF-1 
mRNA (32), so this could have influenced our results in a way that findings regarding 
IGF-1R expression were lower because of possible malnutrition of patients. Third, it 
has been seen that with increasing age a natural decline in IGF-1 occurs (33). With a 
mean age of 63.4 years found in this study it is possible that levels of IGF-1R expression 
were further lowered. However, the mean age of the groups with and without IGF-1R 
expression was not significantly different from each other and by adjusting for age in the 
generalized linear mixed model and the cox regression we partially corrected for this 
effect. Furthermore, interactions with IGF-1R and the abovementioned p53 and HER-
2 have been described (34,35). Thus, the possibility exists that changes in expression of 
IGF-1R were due to changes in p53 and/or HER-2 expression during carcinogenesis. 
Lastly, one of the aims of this study was to assess the influence of DM on IGF-1R 
expression. Because obesity being a risk factor for EAC - with the risk being increased 
up to three times (3,11) - we could not fully adjust for the fact that obesity itself can 
contribute to cancer development. Adipose tissue, and especially visceral adipose tissue, is 
known to cause hyperinsulinemia and higher circulating levels of IGF-1 (3,25). Thus, the 
70
Chapter 4
true influence of DM on the expression of IGF-IR levels could not be assessed. 
Conclusions
Absence or low IGF-1R expression in EAC tumors was associated with high grade 
and advanced tumors, less radical resections and decreased five-year overall survival 
in univariable analyses. IGF-1R might be a possible additional tumor marker for 
carcinogenesis in Barrett’s esophagus since a change in expression patterns was found in 
the course from normal esophageal tissue to invasive adenocarcinoma.  Future studies 
should further investigate the expression of IGF-1R and its exact role in the development 
from Barrett tissue to EAC. Ultimately, this receptor could be used as an additional 
tumor marker for neoplastic progression in Barrett and for survival in EAC and use of 
IGF-inhibiting therapies might become beneficial. 
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Supplemental material
Supplemental table 1. Life table showing numbers at risk and events for five-year disease free survival.
Interval start 
time (months)
Number 
entering 
interval
Number 
withdrawing 
during 
interval
Number 
exposed to 
risk
Number of 
terminal 
events
Proportion 
terminating
Cumulative 
proportion 
surviving 
at end of  
interval
Abs/low IGF
0
12
24
36
48
143
71
50
38
32
20
3
2
1
2
133
69.5
49
37.5
31
52
18
10
5
3
39%
26%
20%
13%
10%
61%
45%
36%
31%
28%
High IGF
0
12
24
36
48  
127
80
55
45
37
10
3
3
2
2
122
78.5
53.5
44
36
37
22
7
6
2
30%
28%
13%
14%
6%
70%
50%
44%
38%
36%
Abs: absent
Supplemental table 2. Life table showing numbers at risk and events for five-year overall survival.
Interval start 
time (months)
Number
entering 
interval
Number 
withdrawing 
during 
interval
Number
exposed to 
risk
Number of 
terminal 
events
Proportion 
terminating
Cumulative 
proportion 
surviving 
at end of 
interval
Abs/low IGF
0
12
24
36
48
143
85
61
43
33
0
0
0
1
2
143
85
61
42.5
32
58
24
18
9
3
14%
28%
30%
21%
9%
59%
43%
30%
24%
21%
High IGF      
0
12
24
36
48  
127
95
67
53
42
0
0
0
0
2
127
95
67
53
41
32
28
14
11
4
25%
29%
21%
21%
10%
75%
53%
42%
33%
30%
Abs: absent
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Chapter 5 Diabetes mellitus does not affect chances for surgery 
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Abstract
Background
The incidence of esophageal adenocarcinoma (EAC) is rising, probably due to a higher 
prevalence of obesity. EAC still has a dismal prognosis despite improved surgical 
techniques. As a result of the increase in obesity, there is also an increase in diabetes 
mellitus (DM). This study therefore investigated the influence of DM on the treatment 
of patients with EAC and whether DM influences mortality.
Methods
All patients with EAC, newly diagnosed between 1998 and 2012, were selected from 
the Eindhoven Cancer Registry. Cox proportional hazards models assessed the influence 
of DM on the treatment of patients with EAC and time dependent cox proportional 
hazards models determined the influence of DM and surgery on mortality. 
Results
A total of 2,729 patients were diagnosed with EAC of whom 426 (16%) were diagnosed 
with DM. During the study period there was a clear increase of patients with DM. The 
presence of DM significantly reduced the chance of surgical treatment in univariate 
analyses (HR 0.81, 95%CI 0.67-0.97), but not in multivariable analyses (HR 0.92, 
95%CI 0.76-1.12). DM did not have any influence on overall mortality (HR 1.11, 
95%CI 0.99-1.24). Surgery decreased overall mortality; diabetics had an HR of 
0.32 (95%CI 0.29-0.36) and non-diabetics and HR of 0.38 (95%CI 0.30-0.49). The 
difference between these groups was not significant (P 0.210).
Conclusions
After adjustment for age, DM did not decrease the number of patients undergoing a 
surgical treatment for EAC. DM had no effect on overall mortality of these patients. This 
could probably be explained by the overall dismal prognosis of EAC. 
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Introduction
The incidence of esophageal cancer has increased over the past decades. This is most 
likely the result of the increased incidence of esophageal adenocarcinoma (EAC), since 
the incidence of esophageal squamous cell carcinoma (ESCC) has remained stable or 
even decreased (1). A reason for this shift in incidence is thought to be the increased 
prevalence of obesity in the Western world (2) since studies have proven that obesity 
is associated with an increased risk of EAC (3, 4). Obesity has been associated with 
Barrett’s esophagus and EAC because of increased intra-abdominal pressure, which may 
promote gastro-esophageal reflux (5, 6). In addition, the prevalence of diabetes (DM) 
also increases due to this rise of obesity (7). Although DM has been linked to cancer 
development in several cancers (8-10), for esophageal cancer, studies report conflicting 
results varying from an increased risk for EAC among diabetics to no increased risk at all 
(11-14). It is thought that hyperinsulinemia, present in patients with obesity and DM, 
upregulates the insulin receptor (IR) and the insulin-like growth factor-I receptor (IGF-
1R). As a result, carcinogenesis is stimulated and prognosis might be influenced (15). 
Because of the increasing incidence of EAC and the potential association between 
DM and EAC – with obesity as a shared risk factor-, it is important to investigate the 
implications that DM might have on the treatment of EAC and its prognosis. 
Esophageal carcinoma still has a dismal prognosis despite improved surgery techniques; 
the five-year survival rate remains only 30% after curatively intended surgery (16). Only 
25% of the patients diagnosed with esophageal carcinoma are eligible and selected for 
surgery (16). An important reason for exclusion from surgery is not only the presence of 
metastatic disease but also a poor physical health, often due to comorbidities (17, 18). 
But because of the improved surgery techniques and postoperative care it is important 
that physicians carefully evaluate patients with comorbidities, to prevent underuse of 
esophagectomy (17). Because of the close link with obesity (and subsequent DM), the 
present study only investigated EAC. The aim of this study was to assess the possible 
implications that DM might have with regard to surgery and overall mortality in EAC.
Methods
Data sources
Data were obtained from the Eindhoven Cancer Registry (ECR) which is maintained by 
the Netherlands Comprehensive Cancer Organisation (IKNL). The ECR records data 
on all patients newly diagnosed with cancer in the Southern part of the Netherlands, an 
area with 2.4 million inhabitants. Six pathology departments, 10 community hospitals, 
and two radiotherapy departments notify the registry. Trained registration clerks actively 
collect data on patient characteristics, cancer diagnosis, staging, comorbidity at cancer 
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diagnosis and initial treatment from hospital medical records. Serious comorbidity that 
could be of influence on prognosis has been recorded in the ECR for all patients since 
1993. Information on initial surgery within nine months after the cancer diagnosis 
(surgery date and operation type) is also collected. The ECR is recognised as high quality 
source for epidemiological research in the Netherlands (19). 
Patient selection
For the present study only patients with EAC, newly diagnosed between 1998 and 2012, 
were studied (n=3102). A diagnosis of EAC was coded according to the International 
Classification of Diseases for Oncology (ICD-O-1, ICD-O-2 and ICD-O-3) (20). The 
TNM classification according to the UICC (Union Internationale Contre le Cancer, 
edition 4.2, 5, 6 and 7) was used to assess pathological tumor stage. All comorbidities 
that were present at the time of cancer diagnosis were recorded according to an adapted 
version of the Charlson comorbidity index (21). All comorbid conditions were scored 
as a dichotomous variable (yes/no). Cardiovascular disease (CVD) included myocardial 
infarction, cardiac insufficiency, angina pectoris, coronary artery bypass graft, peripheral 
artery disease, cerebrovascular diseases and hypertension. DM comprised both type 1 and 
type 2. Patients with missing information on DM were excluded (n=373; 12%). 
Statistical analysis
Follow-up started from the date of cancer diagnosis until the end of the follow-up (death 
or end of study period (December 31, 2013), whichever came first). Additionally, time 
to initial surgery was calculated from the date of the cancer diagnosis until the date of 
operation. 
For comparison at baseline of normally distributed continuous variables, the Student’s 
t-test was used and for categorical variables Chi-square tests were used to assess 
differences between the diabetic and the non-diabetic patients, and between the operated 
and the non-operated patients. 
The influence of age on the chance of surgery was studied with a fractional polynomial 
model. Cox proportional hazards models were carried out to assess if DM was of 
influence on chances to undergo surgery. The effect of a priori established clinically 
relevant confounders (DM, age, sex, lung disease, CVD and CVA (cerebrovascular 
accident)/hemiplegia) on chances to undergo surgery was assessed in multivariable 
models. 
For surgery status survival curves were constructed by using a clock-reset approach, 
divided into two strata. Stratum one contained patients without surgery who were at 
risk until time of death or end of follow up. Patients who got operated were in the first 
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stratum until they got operated; they switched to the second stratum at the time of their 
surgery and were censored in the first stratum from that time. In the second stratum the 
time of surgery was then reset as time for the patients’ further follow-up in the surgery 
group, which ended at death or end of follow-up. Both strata were then subdivided into 
diabetic and non-diabetic groups. 
Furthermore, the differences between the survival curves in the no-surgery and surgery 
groups were assessed with cox proportional hazards regression analyses with time to 
surgery as the time-dependent variable. Additionally, differences between the diabetic 
and the non-diabetic patients were analyzed, thereby creating an interaction between 
DM and the time-dependent variable. By means of likelihood ratio tests survival between 
the groups was compared. Within the surgery group the effect of a priori established 
clinically relevant confounders (DM, age, sex, lung disease, CVD and CVA/hemiplegia) 
on mortality was assessed in multivariable cox proportional hazards models. 
All statistical tests were 2-sided and P-values < 0.05 were considered statistically 
significant. All analyses were performed using SPSS software (SPSS Inc., version 21.0, 
Chicago, Illinois, USA).  
Results
After exclusion of the 373 patients with unknown DM status, the final cohort consisted 
of 2729 patients. The majority of the patients was male (n=2202, 81%). Mean age was 
67.7 (SD 11.6) and mean follow-up was 1.6 years (SD 2.4). A total of 2334 patients 
(86%) died within the follow-up period. The overall rate of surgical intervention was 34% 
(n=934). It appeared that the incidence of DM significantly increased over time in the 
studied cohort. In the group of patients with a cancer diagnosis between 1998 and July 
2005 the incidence of DM was 13% (n=140), while in the group of patients with a cancer 
diagnosis from July 2005 until 2012 the incidence was 18% (n=286) (P=0.001). 
A threshold for age and surgery was determined with a fractional polynomial model. 
Figure 1 shows that patients older than 65 years of age were operated less often. 
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Figure 1. Scatterplot showing cutoff point for surgery at age 65. After 65 years of age  
the chance of receiving surgery decreased. – No Surgery, - Surgery.
Diabetes vs. no diabetes
In table 1 the baseline characteristics for the total cohort according to DM status are 
presented. A percentage of 16% (n=426) was diagnosed with DM. Diabetic patients were 
significantly older (and more often > 65 years of age), had shorter survival, were operated 
less often and received less neoadjuvant therapy. Diabetic patients also suffered more from 
comorbidities and had lower socioeconomic status. 
83
Chapter 5
Table 1. Baseline characteristics of the total cohort of esophageal adenocarcinoma  
patients diagnosed between 1998 and 2012. P-value corresponds with the differences  
between the diabetic and non-diabetic population.  
DM (n=426) non-DM (n=2303) P-value
Sex Male 336 (79%) 1866 (81%)
 Female 90 (21%) 437 (19%) 0.301
Age (mean) 71.3 (SD 9.9) 67.1 (SD 11.8) 0.000
Deceased 374 (88%) 1960 (85%) 0.148
Survival (years, mean) 1.4 (SD 2.0) 1.7 (SD 2.4) 0.029
T-stage TX
 Tis
 T0
 T1
 T2
 T3
 T4 
2 (2%)
0 (0%)
8 (7%)
26 (22%)
29 (24%)
54 (45%)
2 (2%)
44 (5%)
5 (1%)
50 (6%)
150 (19%)
252 (31%)
292 (36%)
19 (2%)
0.209
N-stage NX
 N0
 N1
 N2
 N3
16 (13%)
40 (33%)
46 (38%)
16 (13%)
3 (3%)
98 (12%)
291 (36%)
350 (43%)
55 (7%)
18 (2%)
0.148
M-stage M0
 M1
 Unknown (MX)
77 (77%)
13 (13%)
10 (10%)
479 (70%)
110 (16%)
96 (14%)
0.336
Surgery 122 (29%) 812 (35%) 0.008
Surgery TTE
 THE
 Unknown
30 (25%)
35 (29%)
57 (47%)
217 (27%)
237 (29%)
358 (44%)
0.836
Neo-adj No
 Rtx
 Ctx-Rtx
 Ctx
84 (20%)
2 (1%)
25 (6%)
11 (3%)
510 (22%)
2 (0%)
245 (11%)
55 (2%)
0.004
Comorbid conditions
 Lung disease
 CVD
 CVA/hemiplegia 
77 (18%)
209 (49%)
39 (9%)
307 (13%)
761 (33%)
105 (5%)
0.010
0.000
0.000
SES low
 middle
 high
 institutionalized
122 (29%)
156 (37%)
110 (26%)
32 (8%)
539 (24%)  
901 (40%)
686 (31%)
111 (5%)
0.010
TTE: transthoracic esophagectomy, THE: transhiatal esophagectomy, Neo-adj: 
neo-adjuvant therapy, Rtx: radiotherapy, Ctx: chemotherapy, CVD: 
cardiovascular disease, HT: hypertension, CVA: cerebrovascular accident, 
SES: socioeconomic status. TNM-stage was only available for the operated patients. 
Bold numbers indicate statistically significant differences between both groups. 
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Diabetes and surgery
The univariate cox proportional hazards model showed that diabetic patients were 
operated significantly less often compared to non-diabetic patients (HR 0.81, table 2). 
After adjustment for age the effect of DM on the hazard of receiving surgery disappeared; 
age under or above 65 years appeared to be the variable with the most effect on the 
chances of receiving surgery. After age adjustment the effect of DM on the hazard of 
receiving surgery disappeared. Interactions with DM and age, sex, lung disease, CVD and 
CVA/hemiplegia were not significant (data not shown).  
Table 2. Results of the cox proportional hazards model for the hazard of receiving surgery.
Univariate analysis
HR (95%CI)
2nd model
HR (95%CI)
3rd model
(n=2729)
HR (95%CI)
DM diagnosis yes/no 0.81 (0.67-0.97) 0.88 (0.72-1.06)  0.92 (0.76-1.12)
Age 65 yes/no NA 0.62 (0.55-0.71) 0.67 (0.58-0.76)
Sex NA 0.91 (0.77-1.08) 0.88 (0.74-1.04)
Lung disease yes/no NA NA 0.87 (0.71-1.07)
CVD yes/no NA NA 0.83 (0.71-0.97)
CVA/hemiplegia NA NA 0.67 (0.46-0.98)
DM: diabetes mellitus, CVD: cardiovascular disease, CVA: cerebrovascular accident. Bold numbers indicate 
statistically significant results. 
Diabetes and postoperative overall mortality 
To assess the effect of surgery and DM on postoperative overall mortality a time 
dependent cox proportional hazards model for postoperative overall mortality was 
performed stratified for DM-status and adjusted for age, sex, lung disease CVD and 
CVA (table 3). Operated diabetic patients had lower overall mortality compared to non-
operated diabetic patients (HR 0.32, 95%CI 0.28-0.35, P<0.001, univariate model,  
HR 0.32, 95%CI 0.29-0.36, P<0.001 multivariable model table 3). Similar results were 
seen for operated non-diabetic patients compared to non-operated non-diabetic patients 
(HR 0.37, 95%CI 0.29-0.48, P<0.001, univariate model, HR 0.38, 95%CI 0.30-0.49, 
P<0.001 multivariable model table 3). The difference between these two operated groups 
however, was not significant (P=0.210) as established via the interaction with DM and 
the time dependent variable. 
Diabetes and overall mortality
Diabetic patients did not have different overall mortality compared to the non-diabetic 
patients (HR 1.11, P=0.066, 95%CI 0.99-1.24, univariate analysis) when surgery was not 
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taken into account. The crude overall survival for diabetic patients was 39% at 1 year and 
11% at 5 year, while for non-diabetic patients this was 44% at 1 year and 13% at 5 year. 
Non-operated diabetic patients had an HR for overall mortality of 1.01 (95%CI 0.89-
1.15, P=0.873) for overall mortality in the univariate model compared to non-operated 
non-diabetic patients (HR 1.04, 95%CI 0.91-1.18, P=0.569, multivariable model table 
3). Only age was a significantly associated with mortality in the multivariable model 
(HR1.11, 95%CI 1.01-1.21, P=0.027 table 3). Further interactions with the time 
dependent variable and age, sex, lung disease, CVD and CVA/hemiplegia were not 
significant. 
Table 3. Results of the multivariate time dependent cox 
proportional hazards model on mortality (n=2729).
HR
(95%CI)
P-value
Age < 65 years
 > 65 years
1
1.11
(1.01-1.21)
0.027
Sex male
 female
1
1.09 
(0.99-1.21)
0.090
Lung disease no
 yes
1
0.97 
(0.86-1.09)
0.557
CVD no
 yes
1
1.03 
(0.93-1.13)
0.584
CVA/hemiplegia no
 yes
1
1.20 
(0.99-1.44)
0.059
Within non-DM
    Surgery* no
 yes
1
0.38 
(0.30-0.49)†
< 0.001
Within DM
    Surgery* no
 yes 
1
0.32 
(0.29-0.36)†
< 0.001
Within non-operated
    DM no
 yes
1
1.04 
(0.91-1.18)
0.569
Within operated
   DM no
 yes
1
0.96 
(0.847-1.095)
0.569
*time-dependent factor.
† interaction non-significant (P=0.210)
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Figure 2 additionally visualizes the survival curves comparing the abovementioned 
groups, as assessed via the clock-reset approach as described in the methods section. The 
median overall survival of the operated diabetic group and the operated non-diabetic 
group was 24 and 26.4 months, respectively. The non-operated diabetic group had a 
median overall survival of 7.8 months and the non-operated non-diabetic group had a 
median overall survival of 7.7 months. The difference between the operated and the non-
operated groups was significant (P< 0.001).
Figure 2. Survival curves comparing the operated and the non-operated patients,  
with and without diabetes. 
-DM+, Surg- (n=426), - DM-, Surg- (n=2303), - DM+, Surg+ (n=122), - DM-, Surg+ (n=789).
Survival curves were constructed using a clock-reset approach. Non-operated patients were in the first stratum 
until time of death or end of follow up.  Patients who got operated were in the first stratum until they got operated; 
they switched to the second stratum at the time of their surgery and were censored in the first stratum from that 
time. In the second stratum the time of surgery was then reset as time for the patients’ further follow-up in the 
surgery group. Both strata were subdivided into diabetic and non-diabetic strata. 
Figure 3 additionally provides an overview showing numbers of patients at risk and 
corresponding hazard ratios.
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Figure 3. Overview showing numbers of patients at risk and corresponding hazard ratios (univariable 
analyses). DM = diabetes mellitus. HR of 0.81 indicates significant lower chances of diabetic patients for 
surgery. HR of 1.11 indicates that DM has no significant effect on overall survival. HRs of 0.37 and 0.32 
indicate the decreased mortality within the operated non-diabetic and diabetic patients, respectively. 
* Indicates the non-significant difference between the non-diabetic and diabetic group (P 0.210).
Discussion
The aim of this study was to assess possible implications of DM with regard to surgery 
and prognosis in patients with EAC. It was shown that DM did not decrease the number 
of patients undergoing a surgical treatment for EAC. However it was clear that patients 
above 65 years were less likely to undergo surgery.
An earlier study from the ECR (22) showed that diabetic cancer patients were operated 
less frequently, but with adjustment for age these results were also non-significant with 
regard to chances of surgery in case of esophageal cancer. The 16% prevalence rate of DM 
found in the present study was slightly higher compared to the prevalence rate described 
in this earlier ECR study. These differences can be explained by the fact that the present 
study only analyzed EAC and not ESCC as well. Another possibility is that the rising 
incidence of DM is reflected in this sample that includes more recent EAC diagnoses. 
A study from 2004 in 510 patients found a 15% prevalence rate of DM among patients 
with esophageal or gastroesophageal junction carcinoma (23).
In the present study, DM did not have any impact on overall mortality. The study of 
van de Poll et al (22) also showed that overall mortality was not different in esophageal 
cancer patients with DM compared to those without DM. This is probably due to the 
aggressive behavior of esophageal carcinoma which results in a dismal prognosis; survival 
is so poor that DM cannot be a ‘competing’ cause of death. This is strengthened by a 
study that showed that excess mortality with DM was mostly seen for cancer types with 
long survival rates (24).
Our study showed that diabetic patients who underwent surgery did not have 
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significantly different overall mortality rates when compared to the non-diabetic patients 
who underwent surgery. A study from 2004 (23) reported that DM was a significant 
predictor of mortality in 510 patients undergoing esophagogastrectomy (HR 1.30, 
95%CI 1.09-1.54), however the study does not clearly report whether this concerns 
direct postoperative mortality or overall mortality. Another study in 609 patients 
undergoing surgical resection for esophageal or cardia cancer however, showed that 
DM did not increase postoperative overall mortality (25). Also in our study, we did 
not find any difference in postoperative mortality between patients with or with out 
DM. This can probably be explained largely by selection bias. It can be assumed that 
diabetic patients who are eligible for surgery are in better condition and thus, prognostic 
differences between them and the non-diabetic patients become smaller. 
The overall rate of surgical intervention of 34% found in our study was in accordance 
with an earlier study among 2386 patients with esophageal cancer (17). This study 
reports underuse of esophagectomy in patients with comorbidities and points out the 
need for careful evaluation of patients undergoing esophagectomy since the surgical 
treatment and postoperative care have improved. Our study did not find differences 
in overall mortality after surgery in EAC, which is probably explained by the fact that 
surgeons select the healthiest diabetics for surgery. Possibly, because of improved surgical 
techniques less healthier diabetics might also be eligible for surgery.
However, investigating DM (and other comorbidities) and its prognostic role regarding 
surgery and mortality remains a difficult concept. It is shown that DM, together with 
other concomitant diseases like hypertension and COPD, is one of the most frequently 
occurring comorbidities in the elderly (26). With increasing age, the number of 
comorbidities is likely to increase as well and these can all influence performance status 
and subsequently chances of surgery. Thus, it is difficult to assess the true effect of DM. 
The fact that age alone (> 65 years) influenced chances to undergo surgery in this study 
emphasizes this. However, in the present study patients older than 65 years of age were 
diabetic more often which points out the relationship between increasing age and the 
presence of comorbidities.
This study only investigated EAC because this tumor type is more closely related to 
obesity (3, 4) (and possible subsequent DM) than ESCC, which points out the need 
to distinguish them from each other. Another strength of this study is that we were 
able to adjust for the effect of age by calculating a threshold. Furthermore, DM and 
other comorbidities (like lung disease, CVD and CVA), are related. By checking for 
interactions between diabetes and surgery with these comorbidities, simultaneous 
influences of comorbidities on diabetes and surgery were ruled out. 
However, some limitations of this study should be addressed. This study did not 
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distinguish between insulin-dependent and non-insulin dependent DM and did not take 
metformin use into account. Studies have pointed out insulin as an extra risk factor for 
cancer and metformin as a protective agent in cancer development (27, 28). However, 
a lot of biases were present in early studies investigating glucose-lowering drugs and 
thus the potential risks or benefits are debated (29, 30). Furthermore, information on 
presence of metastasis and tumor stage was not complete for the non-operated patients. 
This could have influenced the results with regard to surgical treatment. Second, for 
44% of the operations the exact type of operation was not known. The possibility exists 
that these unknown operations included staging operations or aborted operations due 
to metastatic disease. This could have influenced prognosis of the operated patients in 
a negative manner and thus the survival difference might be even larger than described. 
Additionally, this study did not analyze cause-specific mortality. It could have been of 
value to distinguish between cancer-specific mortality and death from DM or other 
comorbidities. However, because of the dismal prognosis of esophageal cancer patients 
might be less likely to die from other causes. Lastly, no information on BMI was available. 
Thus, we could not assess DM as an independent risk factor. Obesity has additionally 
been linked to EAC because of increased intra-abdominal pressure, which may promote 
gastro-esophageal reflux disease (GERD) and the development of Barrett’s esophagus 
(5, 6). Information on reflux disease was not known. It can also be assumed that diabetic 
patients are more obese and that this could be of influence on chances of surgery and 
survival. However, studies indicate that obese patients do not have a decreased survival 
after esophagectomy for cancer (31, 32). 
Future research should further study the effect of DM on surgery regarding EAC. 
Overall- and cause specific mortality should be investigated, so the true effect of DM 
(and other comorbidities) on mortality can be assessed. 
To conclude, this study showed that DM did not influence the number of patients 
receiving surgical treatment, nor had an effect on overall mortality in patients with EAC. 
Moreover, the surgeon probably selects only the healthiest diabetic patients for surgery 
since postoperative overall mortality rates of operated diabetic patients were equal to 
those of operated non-diabetic patients. In diabetic patients strict regulation of DM is 
required, in order to keep the patients’ chances for surgery optimal in case of EAC. In 
this way additional comorbidities, that could preclude diabetic patients with EAC from 
surgical treatment, can be prevented and diabetic patients can be operated safely without 
a decreased prognosis. 
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Abstract
Objective
The true rate of new-onset diabetes (NODM) after distal pancreatectomy (DP) is not 
known. This systematic review was carried out to obtain exact percentages regarding the 
incidence of NODM after DP for different indications.
Background
Distal pancreatectomy is the standard procedure for removal of benign or (potentially) 
malignant lesions from the pancreatic body or tail and increasingly used for removal 
of often benign lesions. It is associated with low mortality rates, though postoperative 
diabetes remains a serious problem. 
Methods
Embase, PubMed, Medline, Web of Science, the Cochrane Library and Google Scholar 
were searched for articles reporting incidence of NODM after DP. Methodological 
quality of the included studies was assessed by means of the Newcastle-Ottawa scale for 
cohort studies and the Moga-scale for case series. Mean weighted overall percentages of 
NODM after DP for different indications were calculated with 95% confidence intervals 
(CI) and corresponding P values.
Results
Twenty-six  studies were included, comprising 1.731 patients undergoing DP. The average 
cumulative incidence of NODM after DP performed for chronic pancreatitis was 39% 
and for benign or (potentially) malignant lesions it was 14%. Comparing the proportions 
of these 2 groups showed a significant difference (95%CI 0.351-0.434 and 0.110-0.172, 
respectively, P < 0.000). The average percentage of insulin-dependent diabetes among 
patients with NODM after DP was 77%. 
Conclusions
This review is the largest of its kind to assess the cumulative incidence of NODM after 
DP and shows that NODM is a frequently occurring complication, with incidence 
depending on the preexisting disease and follow-up time. Because NODM can affect 
quality of life, patients undergoing DP should be preoperatively provided with this 
information as specific as possible.
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Introduction
Distal pancreatectomy (DP) (also called left-sided pancreatectomy), with or without 
splenectomy, has been considered the standard procedure for benign or (potentially) 
malignant lesions located in the pancreatic body or tail (1, 2). Still it was little used 
because malignant lesions in the pancreatic tail are often metastasized at the time of 
discovery (3). Today, however, the procedure is increasingly used as the more frequent 
use of modern imaging studies often reveals asymptomatic - and frequently benign - 
pancreatic lesions such as intra pancreatic mucinous neoplasms (IPMNs), which are 
often situated in the pancreatic body or tail (4). As a result of the more benign nature 
of resected lesions, life expectancy after DP has increased. Furthermore, in chronic 
pancreatitis (CP) DP is the treatment of choice in patients with small duct disease 
located in the pancreatic body or tail (5-7). 
DP is associated with low mortality rates, but morbidity, especially pancreatic leak, 
may be high (8, 9). Additionally, postoperative new-onset diabetes (NODM) is a 
concern, although the true rate of NODM after DP is not known. Rates vary from 
5-9% in patients with presumably normal pancreatic parenchyma to 25-50% in patients 
undergoing distal pancreatectomy for chronic pancreatitis (10). Clearly, the risk of 
postoperative diabetes depends on the preexisting disease. Furthermore, the extent of the 
resection logically influences the risk of developing NODM (11). 
The aim of this systematic review is to obtain exact percentages regarding the incidence 
of new-onset diabetes after DP. Preexisting disease, follow-up time and the severity of 
NODM were assessed. The findings obtained from this review could serve to adequately 
inform patients who are planned to undergo DP about the possible consequences. This 
is important especially because diabetes, also in view of the increased life expectancy, can 
become a lifelong complication.
Methods
Study selection criteria and search strategy
Inclusion and exclusion criteria were defined in a review protocol. Eligible studies were 
those that reported at least 10 patients undergoing DP. Studies had to report pre- and 
postoperative numbers of diabetes, or report numbers of NODM postoperatively. Both 
DPs with and without splenectomy could be included, performed either as an open 
procedure or laparoscopically. 
DPs performed for chronic pancreatitis, benign- or (potentially) malignant lesions were 
included. Studies that did not report preoperative numbers of diabetes and did not 
clearly describe numbers of NODM were excluded.
In October 2013, Embase, PubMed, Medline, Web of Science, the Cochrane Library 
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and Google Scholar were searched using the search terms ‘pancreas resection’, ‘distal 
pancreatectomy’, ‘left pancreatectomy’, ‘diabetes mellitus’, ‘pancreas insufficiency’, 
‘endocrine dysfunction’ and ‘pancreatogenic diabetes’, without year or language 
restrictions. 
Studies that seemed to fulfil the eligibility criteria and those for which information in 
the abstract was not sufficient for exclusion were read in full. Bibliographies of included 
publications were searched for other studies and authors were contacted when additional 
unpublished data were needed.  
Data extraction
The 2 authors independently screened titles and abstracts, and full articles if necessary, 
of all citations retrieved from the searches and checked them for eligibility. Any 
disagreement was resolved until consensus was achieved. Figure 1 shows the flowchart of 
the selection of articles for review.
The following data were extracted: numbers of pre- and postoperative diabetes (or 
NODM), duration of follow-up, preexisting disease, whether the operation was 
performed with or without splenectomy, whether the DP was performed open or 
laparoscopically and whether patients with NODM were insulin- or non-insulin 
dependent. Diabetes mellitus (DM) was defined by the criteria for the specific study. If 
a study reported ‘impaired glucose tolerance’, ‘pathological oral glucose tolerance test’ 
(or anything similar) next to reported ‘manifest diabetes’, only the numbers of manifest 
diabetics were used. If a study reported the number of patients available for follow-up, 
that specific number was taken as the initial number of patients undergoing DP. 
Four studies had overlapping cohorts (12-15); only the 2 studies with the largest number 
of patients were included in this review (12, 14).
The methodological quality of included cohort studies was assessed by means of the 
Newcastle-Ottawa scale (NOS) (16). An 18-criteria checklist developed by Moga et al 
(17) served to assess quality of the included case series. Here, a maximum of 18 points 
could be rewarded to each study.
Statistical analyses
If studies did not report the percentage of NODM, this was calculated by one of 
the authors (KB). Furthermore, mean weighted overall percentages of NODM were 
calculated per indication and for NODM being insulin dependent or not. Additionally, 
by calculating 95% confidence intervals and corresponding P-values statistically 
significant differences between the groups were identified. 
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Results
A total of 26 studies were included, comprising 1.731 patients undergoing DP (6, 7, 12, 
14, 18-39). Details of the included studies are summarized in Tables 1, 2 and 3. Table 1 
shows details of the 9 studies reporting CP as the indication for the DP, table 2 shows 
details of the ten studies reporting benign or (potentially) malignant lesions as the 
indication for the DP. Table 3 shows details of the 7 studies reporting both indications.
Figure 1. PRISMA diagram showing selection of articles for review.
Preexisting disease - Chronic pancreatitis
NODM onset less than 6 months postoperative
Four studies reported the incidence of NODM within 6 months after surgery 
(7,29,34,37). Hutchins et al (7) studied 90 patients with chronic pancreatitis who 
underwent DP; 18 patients had developed NODM directly after surgery (20%). Jalleh et 
al (29) described that 7 of the 42 patients were rendered diabetic (17%) within 2 months 
after surgery. The study of Riediger et al (34) described 21 patients undergoing DP; 
only 1 patient had become diabetic immediately postoperatively (4.8%). Govil et al (37) 
reported that 7 patients had become diabetic within 6 months after surgery (18%). 
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NODM onset more than 6 months postoperative
All of the 9 studies reported the incidence of NODM after more than 6 months after 
surgery. Van der Gaag et al (18) studied a cohort of 37 patients that underwent surgery 
for painful CP. However, only 22 patients were available for follow-up. Of these patients, 
10 (45%) developed NODM. DP had an OR of 1.63, albeit non-significantly, for 
developing NODM. Longer follow-up after surgery also increased the risk of NODM. 
A study from Byrne et al (23) contained 41 patients undergoing DP for chronic 
pancreatitis, of whom 15 (37%) developed NODM. Diabetes developed more frequently 
in these patients than in patients undergoing Whipple resections. As described earlier, 
in the study of Hutchins et al (7) 20% of the patients showed NODM at immediate 
postoperative assessment. In the following 27 months, another 14 patients developed 
NODM, increasing the total percentage to 36%. Splenectomy was performed in 61 
patients and this was associated with an increased incidence of NODM compared 
to splenic preservation. In the study of Jalleh et al (29) ten patients became diabetic; 
thus the total percentage of NODM increased to 40%. In 29 cases a splenectomy was 
performed; unfortunately specific outcomes regarding NODM for these patients were 
not reported. Sakorafas et al (14) found a total percentage of 48% for NODM after 
DP. The mean time to onset of diabetes was 3 years in 25 of these patients. The study 
of Schnelldorfer et al (31) reported the highest incidence of NODM after DP of the 
studies included in this review (51%). Of the 69 patients who were available for follow-
up, 35 developed diabetes. In the study of Riediger et al (34) 7 more patients had become 
diabetic at last follow-up, bringing the total incidence of NODM to 38%. Uni- and 
multivariate analyses did not point out any risk factors for the development of NODM. 
The study of Govil et al (37) showed an incidence of NODM of 32%. In addition to 
the 7 patients who developed diabetes within 6 months of surgery, another 5 became 
diabetic. Interestingly, splenectomy was performed in 16 patients and authors reported a 
higher incidence of NODM after splenectomy compared to the spleen-preserving DPs, 
however statistically significant numbers were not reported. In a prospective case series 
studied by Schoenberg et al (6), 74 DPs were performed. Fifteen patients developed 
diabetes. Time to onset of diabetes was not reported and neither was any influence of 
splenectomy, which was performed in 45 cases.
In conclusion, cumulative incidences varied from 20% (6) to 51% (31). Within 6 
months after surgery, the incidence of NODM was 17%, and this increased to 36% 
when percentages of NODM after longer follow-up periods of these 4 studies only were 
combined. Overall, the incidence of NODM was 39% when the numbers of new-onset 
diabetic patients at the latest follow-up of all 9 studies were combined.
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Table 1. Summary of included studies reporting DP for chronic pancreatitis
Reference Study 
type
Study 
quality
*†
Mean 
FUP 
(yrs)
No. 
pati-
ents
DM 
diagnosis
Total 
DM 
preop 
DM 
< 6 mo
DM > 6 
mo
Total 
DM 
postop
% 
NODM
(no. 
patients)
Sple-
nec-
tomy
van der 
Gaag et al, 
2012 18
Prospec
tive 
cross-
sectional 
cohort 
study
7/9* 5.3 22 FBG, 
HbA1C, 
need for
Medi-
cation
4 NR 10 14 45%
(10)
NR
Byrne et 
al,
1997 23
Retro
spective
cohort 
study
7/9* 6.8 41 NR 6 NR 15 21
(20 
IDDM)
37%
(15)
NR
Hutchins 
et al, 
2002 7
Retro
spective
case 
series
15/18† 2.8 90 OGTT 8 18 14 40 36%
(32)
61
Jalleh et 
al, 1992 29
Retro
spective
cohort 
study
6/9* 1.7 42 Need for 
diet or 
medi-
cation, 
OGTT
1 7 10 18 40%
(17)
29 
Sakorafas 
et al, 2000 
14
Retro
spective
cohort 
study
8/9* 7.9 135 NR 12 NR 65 77 48%
(65)
11
Schnell-
dorfer et 
al, 2007 31
Retro
spective
cohort 
study
6/9* 5.5 69 NR NR NR 35 35 51%
(35)
NR
Riediger 
et al,  
2007 34
Prospec
tive
cohort 
study
9/9* 4.7 21 WHO-
criteria, 
OGTT
4 1 7 12 38%
(8)
NR
Govil et 
al, 1999 37
Retro
spective 
case 
series
11/18† 4 38 NR 4 7 5 16 32%
(12)
16
Schoen-
berg et al, 
1998 6
Prospec
tive case 
series
12/18† 4.8 74 OGTT, 
WHO-
criteria
12 NR 15 27 20%
(15)
45 
Total - - 4.8 532 - 51 33 176 260 39%(209)
(95%CI 
0.351-
0.434)
162
*NOS quality assessment.
†Moga quality assessment. 
FBG indicates fasting blood glucose level; FUP, follow-up; NR, not reported; OGTT, oral glucose tolerance test
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Preexisting disease  – Benign or (potentially) malignant lesions
NODM onset less than 6 months postoperative 
Two studies reported incidences of NODM within 30 days after surgery (32, 33). 
Lebedyev et al (32) performed a consecutive series of laparoscopic DPs. The incidence of 
NODM was 17%. Splenectomy was performed in 5 patients, however the incidence of 
NODM for this group was not reported. Mori et al (33) described a group of 14 patients 
undergoing DP; only 1 patient developed NODM (7%).
NODM onset more than 6 months postoperative
Regarding longer durations of follow-up, 8 studies reported benign or (potentially) 
malignant lesions as the indication for surgery (12, 21, 24-27, 35, 36). Balzano et al (21) 
reported that 3 patients became diabetic after DP (14%). Eleven patients underwent 
splenectomy, but the study did not assess the effect on the development of NODM. 
A retrospective cohort study performed by Dumitrascu et al (24) analyzed spleen-
preserving DPs. Three patients (12%) developed NODM and this was not significantly 
different from central pancreatectomy to which the DPs were compared with. What 
this study did show was that the length of the resected pancreas was significantly greater 
in the DP group than in the central pancreatectomy group (8.5cm vs. 5 cm). DiNorcia 
et al (25) compared DP with central pancreatectomy as well. Incidence of NODM was 
28% in the DP-group, and this was not significantly different from the group undergoing 
central pancreatectomy. Another study comparing central pancreatectomy with DP 
(26) found an overall incidence of 23% for NODM. The incidence was significantly 
higher for patients who underwent DP compared to patients who underwent central 
pancreatectomy. Falconi et al (27) described 7 patients (14%) with NODM after DP. 
In this study, a significant hazard ratio of 12 for developing pancreatic insufficiency 
was found. However, the analysis did not distinguish between exocrine and endocrine 
dysfunction. The study of Lee et al (12) investigated 188 patients undergoing DP. Twenty 
of them developed diabetes (11%). No significant differences in incidence of NODM 
between DP with splenectomy, spleen-preserving DP and central pancreatectomy were 
found. A study that compared DP to central pancreatectomy found and incidence of 17% 
for NODM after DP (35). The incidence of NODM in patients who underwent DP was 
significantly higher than in the patients who underwent central pancreatectomy. Xiang et 
al (36) investigated 55 patients undergoing DP, 5 of whom developed NODM (9%). The 
incidence of NODM after central pancreatectomy was zero.  
Summarized, cumulative incidences varied from 7% (33) to 28% (25). The 2 studies 
reporting incidence of NODM within 6 months after surgery had an overall percentage 
of 12%. A possible increase in incidence of NODM over time could not be assessed since 
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these studies did not report numbers of NODM after longer periods of time. When 
the percentages of NODM of the studies reporting after 6 months of follow-up were 
combined, the overall percentage was 14%.
Table 2. Summary of included studies reporting DP for benign or (potentially) malignant lesions
Reference Study 
type
Study 
quality
*†
Mean 
FUP
(yrs)
No. 
pati-
ents
DM 
diagnosis
Total 
DM 
preop 
DM 
< 6 mo
DM > 6 
mo
Total  
DM 
postop
% 
NODM
(no. of 
patients)
Sple-
nec-
tomy
Balzano et 
al, 2003 21
Retro
spective
cohort 
study
7/9*    5.5 21 Tele-
phone 
inter
view
2 NR 3 5 14%
(3)
11
Dumi-
trascu et 
al, 2012 24
Retro
spective
cohort 
study
8/9* 3.9 25 FBG 1 NR 3 4 12%
(3)
No
DiNorcia 
et al, 2010 
25
Retro
spective
cohort 
study
7/9* 2.6 50 Dietary 
restric-
tion, need 
for medi-
cation
11 NR 14 25 28%
(14)
NR
Hirono et 
al, 2009 26
Prospec
tive
cohort 
study
6/9* 2.2 26 FBG, 
HbA1C. 
OGTT. 
Need for 
diet or 
medi-
cation
3 NR 6 9 23%
(6)
26
Falconi et 
al, 2006 27
Prospec
tive
cohort 
study
8/9* NR 50 FBG, 
OGTT
12 NR 7 19 14%
(7)
NR
Lee et al, 
2010 12
Retro
spective
cohort    
study
8/9* 2.9 188 NR 20 NR 20 40 11%
(20)
143
Lebedyev 
et al, 2004 
32
Retro
spective
case 
series
7/18† NR 12 NR NR 2 NR 2 17%
(2)
5 
Mori et al, 
2012 33
Prospec
tive
cohort 
study
7/9* NR 14 FBG, 
OGTT
8 1 NR 6 
(some 
became 
non-
DM)
7%
(1)
NR
Shikano et 
al, 2010 35
Retro
spective
cohort 
study
9/9* 5.9 35 HbA1C, 
FBG
NR NR 6 6 17%
(6)
NR
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Xiang et 
al, 2012 36
Retro
spective
cohort 
study
7/9* 1.4 55 (F)BG 1 NR 5 6 9%
(5)
NR
Total - - 3.5 476 - 58 3 64 122 14% (67)
(95%CI 
0.110-
0.172)
185
*NOS quality assessment. 
†Moga quality assessment. 
FBG indicates fasting blood glucose level; FUP, follow-up; NR, not reported; OGTT, oral glucose tolerance test
Preexisting disease  – CP and benign or (potentially) malignant lesions
NODM onset less than 6 months postoperative 
Three studies reported the incidence of NODM directly postoperative (20, 38, 39). 
Belyaev et al (20) studied 25 patients who underwent DP and 7 of them developed 
diabetes (28%). CP was the indication for surgery in 10 patients. Patients with exo- or 
endocrine insufficiency after DP suffered more losses in quality of life scores. Irani et 
al (38) studied 171 patients, with 75 patients undergoing DP as part of a multivisceral 
resection. A total of 13 patients had CP as the preexisting disease. Only 6 patients 
developed diabetes (4%). The incidence of NODM did not differ significantly between 
the regular DP-group and to the DP-group undergoing multivisceral resection. In the 
study of Lillemoe et al (39) CP was the preexisting disease in 56 patients. The incidence 
of NODM was 6%. In 198 patients a splenectomy was performed and these patients 
did not have more postoperative complications than patients in whom the spleen was 
preserved. However, incidence of NODM was not reported.
NODM onset more than 6 months postoperative
Four studies reported the incidence of NODM after more than 6 months after surgery (19, 
22, 28, 30). Stutchfield et al (19) reported that 17% of patients developed diabetes after DP. 
In 6 cases of postoperative pancreatic insufficiency the resected specimen showed CP; it was 
not mentioned however whether these were tissues from patients with endo- or exocrine 
insufficiency. Furthermore, 50 patients underwent splenectomy, but NODM in these 
specific patients was not reported. Adam et al (22) found a 5% incidence rate of NODM 
after DP; 21 of the 41 patients who underwent DP (51%) had preexisting CP. The spleen 
was removed in 37 patients but NODM was not described for this specific group. King et 
al (28) reviewed 125 consecutive patients undergoing DP; 11 had preexisting CP. Ten of all 
patients developed diabetes (8%). The study described a trend towards an increasing risk of 
NODM in patients with a history of pancreatitis (OR 2.9). A study that assessed pancreatic 
volume as a predictor for NODM found a 36% incidence of NODM in patients who 
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underwent DP (30). In comparison with patients who did not develop diabetes, patients 
with NODM had a significantly higher percentage of resected volume, a lower volume of 
remnant normal parenchyma and a higher volume of resected normal parenchyma. 
To conclude, cumulative incidences varied from 4% (38) to 36% (30). The 3 studies 
that assessed incidence of NODM directly postoperative had an overall percentage of 
6%. A possible increase in incidence of NODM over time could not be assessed since 
these studies did not report NODM incidences after longer periods of time. The overall 
percentage of NODM of all 7 studies combined was 10%.
Table 3. Summary of included studies reporting DP for CP and benign or (potentially) malignant lesions
Reference Study 
type
Study 
quality
*†
Mean 
FUP
(yrs)
No. 
pati-
ents
DM 
diagnosis
Total 
DM 
preop 
DM 
< 6 mo
DM > 6 
mo
Total  
DM 
postop
% 
NODM
(no. of 
patients)
Sple-
nec-
tomy
Stutch-
field et al , 
2008 19
Retro
spective
case 
series
12/18† 0.7 65 Need for 
medi-
cation
NR NR 11 11
(9 
IDDM) 
17%
(11)
50  
Belyaev et 
al, 2013 20
Retro
spective
cohort 
study
7/9* NR 25 Need for 
medi-
cation
3 7 NR 10 28%
(7)
NR
Adam et 
al, 2001 22
Prospec-
tive
case 
series
9/18† NR 41 NR 7 NR 2 9 5%
(2)
37
King et al, 
2008 28
Retro
spective
case 
series
12/18† 1.8 125 Need for 
medi-
cation
14 NR 10 24 8%
(10)
105
Shirakawa 
et al,  
2012 30
Retro
spective
case 
series
13/18† 2.2 61 FBG, 
OGTT
0 0 22 22 36%
(22)
NR
Irani et al, 
2008 38 
Retro
spective 
case 
series
9/18† NR 171 NR NR 6 NR 6 4% (6) NR
Lillemoe 
et al,  
1998 39
Retro
spective
case 
series
9/18† NR 235 NR 6 13 NR 19 6%
(13)
198
Total - - 1.6 723 - 30 26 45 101 10% (71)
(95%CI 
0.077-
0.120)
390
*NOS quality assessment. 
†Moga quality assessment. 
FBG indicates fasting blood glucose level; FUP, follow-up; NR, not reported; OGTT, oral glucose tolerance test
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Insulin vs. non-insulin dependent NODM
Nine studies reported insulin-dependent DM (IDDM) among NODM-patients and 
thus described its severity (19, 22, 23, 25, 27, 29, 35, 38, 39). Indications for surgery were 
CP, as well as benign, low grade or (potentially) malignant lesions. 
Stutchfield et al (19) reported that 9 of the 11 patients who developed NODM were 
insulin-dependent (82%). The study of Adam et al (22) described that both patients who 
developed NODM after DP had become insulin-dependent. Byrne et al (23) described 
that 20 of the 21 patients with postoperative DM were insulin-dependent. However, 
information is lacking on whether this 1 patient who was not insulin-dependent had 
NODM or was diabetic preoperatively. Nevertheless, incidence of IDDM among the 
new-onset diabetes group would be between 93% and 100%. The retrospective study 
performed by DiNorcia et al (25) reported that 5 of the 14 patients with NODM 
had IDDM (36%). Falconi et al (27) described 7 patients who had become diabetic 
postoperatively; 3 of them were insulin-dependent (43%). In the study of Jalleh et al (29), 
17 patients developed NODM and 14 of them became insulin-dependent diabetics 
(82%). Shikano et al (35) reported that 6 patients who underwent DP developed 
NODM. Three of them were dependent on insulin at the last follow-up. The study of 
Irani et al (38) described 6 patients who developed NODM, all of them being insulin-
dependent diabetics. Lillemoe et al (39) also reported that all 13 patients with NODM 
needed insulin for glucose control. 
In conclusion, the incidence of IDDM among patients with NODM varied from 36% 
to 100%. The overall percentage of IDDM among these new-onset diabetics was at least 
77%.
Comparison of overall percentages
To determine whether the overall percentages between the groups were significantly 
different from each other 95% confidence intervals and P-values were calculated. When 
the overall percentage of the CP-group (39%) was compared with the overall percentage 
of the group with benign or (potentially) malignant lesions (14%), nonoverlapping 
confidence intervals were found (0.351-0.434 and 0.110-0.172 for the CP-group and 
the lesion-group, respectively), indicating a statistically significant difference (P<0.001). 
When the overall percentage of the CP-group (39%) was compared to the overall 
percentage of the group with CP and benign or malignant lesions (10%), these also 
seemed to be statistically significant (95%CI 0.351-0.434 and 0.077-0.120 respectively, 
P<0.001). When the overall percentage of the group with benign or malignant lesions 
(14%) was compared with the overall percentage of the group with CP and benign 
or malignant lesions (10%), another significant difference was found (95%CI 0.110-
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0.172  and 0.077-0.120, respectively, P=0.024). Furthermore, when the subgroups with 
information regarding NODM within or after 6 months of follow-up were compared, 
either within each main group or in between the 3 groups, this all rendered statistically 
significant differences (data not shown).
Discussion
This systematic review aimed to obtain exact percentages for NODM after DP for 
different indications. When the DP was performed for chronic pancreatitis the overall 
cumulative incidence of NODM at latest follow-up was 39%. When the DP was 
performed for benign or (potentially) malignant lesions the overall cumulative incidence 
was 14%, significantly lower than when the DP was performed for CP. The overall 
percentage of NODM in studies that reported both chronic pancreatitis and benign or 
malignant lesions as the indication for surgery was 10%. In order to get an impression of 
the severity of the NODM, insulin dependency was reviewed. On average, 77% of the 
patients with NODM were dependent on insulin.  
A possible explanation for the higher occurrence of NODM in patients undergoing DP 
for chronic pancreatitis is probably the ongoing destruction of pancreatic parenchyma 
in these patients (40). In patients with benign or malignant lesions, the remaining 
pancreatic parenchyma is healthy, and these patients have lower risk for developing 
NODM. Nevertheless, it is hard to distinguish whether postoperative changes are 
completely due to surgery or also due to the preexisting disease. In most cases it is likely 
to be a combination of both (41). Furthermore, a long follow-up period is necessary in 
these patients to make sure a diabetes diagnosis is not missed. This because this review 
showed an increase in incidence of NODM after DP for chronic pancreatitis with longer 
durations of follow-up. 
Pancreatogenic diabetes, as the new-onset diabetes following pancreatic disease and/
or pancreatic resection has been named, is seen in approximately 9% of the general 
diabetic population; 2-3% of whom have undergone pancreatectomy (42). In a study 
on pancreatoduodenectomy, incidences for NODM varied between 20 and 50% (43), 
reasonably in line with the findings from this review. 
There is reason for concern, since in general, the patients who undergo DP are relatively 
young. First, diabetes impacts quality of life. As described by Belyaev et al (20), patients 
who postoperatively developed endo- or exocrine insufficiency, or both, suffered more 
losses in their physical quality of life. A study comparing quality of life after total 
pancreatectomy and partial pancreatic resection found that postoperative diabetes after 
both procedures had the largest negative impact on leisure and physical activities (44). 
Second, 77% of the patients with NODM studied in this review had IDDM, which 
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has more impact on quality of life than only dietary restrictions or use of OGLD (45). 
Furthermore, pancreatogenic diabetes seems to be similar to type 2 diabetes with regard 
to glucose tolerance and insulin resistance. However, glucose control is more difficult due 
to severe fluctuations in glucose-levels associated with treatment of exogenous insulin 
(46) and deficiency of pancreatic polypeptide (47). Lethal episodes of hypoglycemia 
– due to the absence of glucagon in combination with an ongoing need for exogenous 
insulin - have been described in patients who underwent pancreatoduodenectomy (48). 
Because the glucagon-producing alpha-cells are located mainly in the pancreatic body 
and tail, patients undergoing DP can be especially at risk for severe hypoglycemia. Third, 
there is increasing evidence that diabetes is associated with an increased risk of developing 
several cancers and cancer mortality (49-51). Insulin therapy is thought to increase cancer 
risk even more, whereas metformin use is thought to decrease cancer risk (51,52). A 
review of Cui et al (46) addressed concern over the increased cancer risk associated with 
insulin use among patients with pancreatogenic diabetes. In conclusion, the young age 
of the patients undergoing DP, together with their increasing life expectancy, may cause 
problems in the future. Patients might not only live the rest of their lives in poorer health, 
with ‘brittle’ diabetes, but they also might be at risk of developing cancer because they 
have become dependent on insulin. 
Strengths and limitations
This review included the largest number of patients so far compared with other reviews 
assessing cumulative incidence of NODM after DP. By calculating mean weighted 
overall percentages for NODM, more clarity on its incidence regarding the indication 
for DP and the severity of the NODM was given. However, some limitations should 
be addressed. For one, in some cases more parenchyma than the usual 40-60% was 
resected and not all studies included in this review reported the resected percentage of 
pancreatic parenchyma. Byrne et al23 described that in 80% of the patients 40-50% of the 
pancreatic parenchyma was excised. However, in some cases the DP included a 30-70% 
resection. Hutchins et al (7) reported that the median volume of resection was 50%, but 
with a range of 10-90% and that the size of the pancreatic remnant unsurprisingly was 
significantly associated with the development of NODM. In the study of Jalleh et al (29) 
DPs with 40-70% resection were described. Govil et al (37) reported that the resection 
usually included 40% of the volume of the pancreas. In the study of Schoenberg et al (6) 4 
patients underwent subtotal pancreatectomy and in the study of Lillemoe et al (39) 85% 
of the pancreas was resected in 10 patients. Thus, not all patients underwent an equal 
resection and this could have influenced the outcome in terms of NODM.
Second, not all studies used the same criteria for establishing diabetes diagnosis and 
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some studies did not report how diabetes diagnosis was assessed. With 1 study having 
more stringent criteria for diabetes than the other, numbers of patients with NODM 
might be even higher than reported. Third, some studies report substantial dropout rates 
in follow-up or do not have a sufficient follow-up period, which increases the risk that 
numbers of NODM are underreported. Fourth, only few studies reported whether the 
DP was performed laparoscopically (19, 24, 32, 38). Most studies that did not report this 
were older, and it is likely that the DPs in these studies were performed via laparotomy. 
Still, this would not seem to affect the results as a meta-analysis proved that laparoscopic 
DP is a safe procedure and is comparable to the open procedure (53). Lastly, not all 
studies reported whether the DP was performed with or without splenectomy. Three 
studies assessed whether splenectomy increased the risk of NODM (7,12,37). In 1 study, 
splenectomy was not associated with an increased risk of NODM (12) and in 2 studies, 
splenectomy was (7,37). Furthermore, analyzing studies that report CP as well as benign 
or malignant lesions as the indication for the DP might not be correct since they are 
associated with very different outcomes regarding NODM, as seems from this review.
This review emphasizes the need to avoid NODM. We recommend more studies 
comparing DP to other procedures that are more parenchyma sparing, like central 
pancreatectomy. This procedure seems to carry lower risk of NODM; however, it is 
associated with an increased incidence of postoperative pancreatic fistula when compared 
to DP (54,55). Furthermore, risk of a nonradical resection is present since in some cases 
resected lesions - which preoperatively appeared benign - postoperatively appeared to 
be an invasive malignancy (28). Thus, a solution for NODM is not expected in the near 
future.
Conclusions
This systematic review assessed different modalities regarding NODM after DP and 
revealed a 39% incidence of NODM when the DP was performed for CP. For benign 
or (potentially) malignant lesions the incidence was 14%. Until other procedures have 
definitively proven to be safer, DP cannot be avoided and the risk of NODM has to be 
taken for granted. Patients must be clearly informed about this before they undergo DP.
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Abstract
Background
Distal pancreatectomy (DP) is an increasingly performed procedure because of increased  
detection of asymptomatic, potentially malignant pancreatic lesions. DP is considered 
a safe procedure however morbidity may be high. This case series studied endo- and 
exocrine pancreatic function and quality of life after DP in patients with and without an 
asymptomatic pancreatic lesion. 
Methods
A total of 143 patients who underwent distal pancreatectomy in a tertiary referral 
hospital in the Netherlands were retrospectively analyzed. Asymptomatic lesions were 
defined as lesion found by imaging techniques performed for other indications than 
pancreatic disease. From 44 eligible patients information on pancreatic function and 
quality of life was obtained in the outpatient clinic. New-onset diabetes (NODM), 
exocrine insufficiency and quality of life were statistically analyzed in (a)symptomatic 
patients. 
Results
In 30% the DP was performed for an asymptomatic lesion and intraductal papillary 
mucinous neoplasm (IPMN) was the most frequent diagnosis within this group (39%). 
Asymptomatic patients were older (P=0.006). The overall rate of NODM was 43%, 
with IPMN being associated with NODM (P<0.001). New exocrine insufficiency 
developed in 43% of the patients and additional splenectomy was associated with new 
exocrine insufficiency (P=0.024). Asymptomatic patients reported better mental health 
(P=0.023) compared to symptomatic patients. 
Conclusions
This case series found that 30% of the patients underwent DP for an asymptomatic lesion 
and IPMN was the main diagnosis in this group. IPMN was associated with NODM, 
however this had no effect on quality of life. Larger studies should further assess the 
harm that might be done to patients who undergo resection because of an asymptomatic 
pancreatic lesion. 
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Introduction
Distal pancreatectomy (DP) is increasingly being performed due to the increased 
detection of asymptomatic, potentially premalignant or malignant pancreatic lesions, 
which are related to the growing use of cross-sectional imaging for other indications (1-
3).  
Such ‘incidentalomas’, as these lesions are called, are defined as an asymptomatic mass 
incidentally detected by a diagnostic test, usually an imaging study (4, 5). Intraductal 
papillary mucinous neoplasm (IPMN) seems to be the most common asymptomatic 
lesion leading to surgical resection (6). However, only a few studies on this topic 
have been published and most of them are small. The need for surgery in case of an 
asymptomatic lesion depends on the (suspected) diagnosis. For solid lesions, suspicion of 
malignancy is usually high and surgery is the only potentially curative treatment. In cystic 
lesions, however, chances for malignancy differ by demographic, radiographic and clinical 
findings and surgery is often not indicated (7).
The amount of pancreatic tissue resected during DP concerns the portion of the pancreas 
that extends to the left of the midline and the resection follows - in most patients - the 
course of the superior mesenteric vein although on indication less pancreas parenchyma 
may be resected. DP is considered a safe procedure because of 0-2% mortality rates (8, 
9). Postoperative morbidity however, can be substantial with rates of clinically relevant 
complications up to 47% (8). Postoperative pancreatic fistula (POPF) after DP remains 
a very common (30%) problem (8-10), as well as new-onset diabetes mellitus (NODM), 
with incidences of NODM varying per underlying disease (11).
Higher postoperative morbidity (mainly POPF) among patients who underwent 
surgery for an asymptomatic lesion compared to patients who underwent surgery for 
a symptomatic lesion has been reported (6). It can be hypothesized that postoperative 
complications in asymptomatic patients have greater impact on physical and mental 
health compared to patients who were already symptomatic before surgery.
Therefore, this study analyzed a series of DPs performed for various indications in 
a tertiary referral hospital in the Netherlands. The rate of asymptomatic lesions was 
studied, as well as the rate of postoperative complications with focus on pancreatic endo- 
and exocrine insufficiency. This study also aimed to provide more insight in postoperative 
morbidity and quality of life after DP, thereby studying patients with and without an 
asymptomatic lesion. 
Methods
This study was performed according to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement (12). A number of 143 patients who 
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underwent distal pancreatectomy from January 2001 until December 2012 at the 
Erasmus University Medical Center in Rotterdam were retrospectively analyzed. 
Surviving patients were contacted by telephone and asked whether they were willing to 
participate in the study or not. Patients who underwent distal pancreatectomy with or 
without splenectomy either via laparoscopic or open approach were included. Patients 
with a history of previous pancreatic surgery were excluded. 
Data collection
Data on whether the pancreatic lesion was incidentally identified, body mass 
index (BMI), surgery, postoperative complications and pathological outcome were 
retrospectively reviewed using medical records. Patients were asked to visit the outpatient 
clinic where additional information on diabetic status, information on physical health 
and quality of life was obtained using a validated questionnaire. Additionally, blood and 
stool samples were drawn to assess pancreatic function. The medical ethics committee 
approved the study and all patients signed informed consent. 
Definition of complications
Postoperative complications were subdivided into POPF, intra-abdominal abscess, 
post pancreatectomy hemorrhage (PPH), wound infection or other. POPF and PPH 
were scored using the recommended definitions of the International Study Group of 
Pancreatic Surgery (ISGPS) (13, 14). Complications were additionally scored according 
to the Clavien-Dindo classification of surgical complications (15). Only clinically 
relevant complications (> grade 2) were studied. 
Definition of asymptomatic pancreatic lesions
A pancreatic lesion was defined asymptomatic if the lesion was encountered during the 
workup for atypical abdominal signs or for symptoms not associated with pancreatic 
disease (acute or chronic pancreatitis, jaundice, steatorrhea etc.), or as a lesion that 
was discovered during regular follow-up of other diseases or routine (radiologic) 
examinations.
Definitions of new-onset diabetes mellitus and new exocrine dysfunction 
Pancreatic endocrine function was assessed using the non-fasting plasma glucose 
concentration and glycated hemoglobin (HbA1c). NODM was defined as a non-fasting 
glucose level above 11.0 mmol/l (200 mg/dl) or a glycated hemoglobin above 42 mmol/
mol or a need for use of glucose lowering drugs after surgery in patients who were 
reported to be non-diabetic before surgery. Furthermore, the type of the glucose-lowering 
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drug used (metformin, SU-derivatives, insulin, or other) was obtained. The start date of 
the glucose-lowering drug was also obtained if available. The duration from surgery to 
onset of NODM was calculated in months using the date of operation and the date of the 
first use of any glucose-lowering drug. In patients with NODM but without the need for 
medication the date the blood sample was drawn was used. A subdivision was made into 
early (< 6 months after surgery) and late onset (> 6 months after surgery) of NODM. 
Pancreatic exocrine function was analyzed by measuring elastase-1 levels in stool samples. 
A patient was considered to have new exocrine dysfunction when the elastase-1 level was 
less than 200 µg/gr or the patient needed to use enzyme supplements after surgery.
Quality of life
Quality of life was assessed by using the Short Form-36 (SF-36) Health Survey 
questionnaire, a well-known and validated self-report inventory with eight domains 
focusing on physical and mental health (16). These eight domains are grouped into a 
Physical Component Summary (PCS) and a Mental Component Summary (MCS). The 
quality of life of patients included in this study was age-matched and compared to the 
quality of life of the average Dutch population. Information about this cohort can be 
found elsewhere (17).
Statistical analyses
Follow-up was defined in years starting from the day of surgery until the date of latest 
follow-up.  
For comparison at baseline of normally distributed continuous variables, the independent 
student’s t-test was used and for categorical variables the Chi-square test was used. 
The Fisher’s exact test was used when cells in cross tabulations contained less than 5 
observations. With regard to quality of life confidence intervals were calculated using 
the mean (mean +/-1.96*SD). By checking for overlap between the confidence intervals 
statistical significance was assessed. All statistical tests were 2-sided and P-values < 0.05 
were considered statistically significant. All analyses were performed using SPSS software 
(SPSS Inc., version 21.0, Chicago, Illinois, USA).  
Results
As mentioned above, 143 patients underwent distal pancreatectomy of whom 36% 
(n=51) had been diagnosed with an asymptomatic pancreatic lesion. In eight patients 
it was unknown whether the pancreatic lesion was an incidental finding thus these 
patients were excluded. In total, a percentage of 55% was female (n=74) and the mean 
age of the total cohort was 53.5 (SD 15.3) years. Asymptomatic patients were older than 
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symptomatic patients (59.4 years (SD 12.6) vs. 50 years (SD 15.8), P < 0.001), and the 
most frequent diagnosis among asymptomatic patients was cancer (30%), followed by 
IPMN and MCN (14% for both). 
Of all potentially eligible patients, a total of 19 patients had died (four postoperatively, 
four of disease specific causes, five from other causes unrelated to disease or surgery and 
in six patients the cause of death was unknown). Three surviving patients had previous 
pancreatic surgery and were excluded. A number of 77 patients were not willing or able 
to participate in the study. Finally, 44 patients were included. Further analyses were 
performed in these patients only. 
Mean age at time of surgery was 54.6 (SD 13.7), 57% was female (n=25) and mean 
follow-up was 4.3 years (SD 2.7). Other baseline characteristics are shown in table 1. 
Pathology revealed neuro-endocrine tumors (NET) (n=16, 36%), intraductal papillary 
mucinous neoplasms (IPMN) (n=8, 18%) and chronic pancreatitis (n=8, 18%) as most 
common diagnoses. Of the eight patients with IPMN two were thought to have a main 
duct IPMN (25%), two a side branch IPMN (25%), two a mixed type IPMN (25%) 
and from two patients the type of IPMN was unknown. Other diagnoses concerned 
metastasis of an ovary tumor and two concerned traumatic pancreatic rupture. 
The overall rate of clinically relevant (Clavien Dindo > grade 2) postoperative 
complications was 14% (n=6, table 1). 
Table 1. Baseline characteristics describing the cohort of 44 patients. 
Total Symptomatic  
(n=31)
Asymptomatic
(n=13)
P-value
Female 25 (57%) 20 (65%) 5 (38%) 0.111
Age (mean)  54.6 (SD 13.7) 51.6 (SD 4.45) 61.8 (SD 8.7) 0.006
Body mass index (mean)*  25.4 (SD 3.4) 25 (SD 3.3) 26.3 (SD 3.6) 0.267
Follow up (mean, years)  4.3 (SD 2.7) 4.8 (SD 3.1) 3 (SD 1.04) 0.004
Diagnosis 
Chronic pancreatitis
Neuroendocrine tumor
Pseudocyst, cystadenoma
IPMN
Mucinous cystic neoplasm
Carcinoma
Other
8 (18%)
16 (36%)
3 (7%)
8 (18%)
5 (11%)
1 (2%)
3 (7%)
7 (23%)
14 (45%)
2 (7%)
3 (10%)
2 (7%)
1 (3%)
2 (7%)
1 (8%)
2 (15%)
1 (8%)
5 (39%)
3 (23%)
0 
1 (8%) 0.074
Operation type body-tail
tail
14 (32%)
30 (68%)
9 (29%)
22 (71%)
5 (39%)
8 (62%)
0.540
Splenectomy 15 (34%) 10 (32%) 5 (39%) 0.692
Laparoscopy 8 (18%) 7 (23%) 1 (8%) 0.402
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Complications none
POPF
Intra-abdominal abscess 
PPH
wound infection
other
30 (68%)
5 (11%) (all gr. B)
1 (2%)
2 (5%)
1 (2%)
5 (11%)
21 (68%)
3 (10%)
1 (3%)
2 (7%)
1 (3%)
3 (10%)
9 (69%)
2 (15%)
0
0
0
2 (15%)
0.913
Clavien-Dindo 3A
3B
4A
4 (9%)
1 (2%)
1 (2%)
2 (7%)
1 (3%)
0 
2 (15%)
0 
1 (8%)
 0.458
Reoperation 1 (2%) 1 (3%) 0 1.000
Preoperative diabetes 6 (14%) 5 (16%) 1 (8%) 0.652
New-onset diabetes 19 (43%) 11 (36%) 8 (62%) 0.111
Preoperative enzyme supple-
ment
3 (7%) 3 (10%) 0 0.544
Postoperative exocrine insuf-
ficient
19 (43%) 15 (48%) 4 (31%) 0.335
MCS (mean) 79.1 (SD 16.5) 75.5 (SD 16.9) 87.7 (SD 11.9) 0.023
PCS (mean) 79.3 (SD 21.1) 76.8 (SD 21.7) 85.3 (SD 19.3) 0.226
BMI: body mass index, IPMN: intraductal papillary mucinous neoplasm, POPF: postoperative pancreatic 
fistula, PPH: post pancreatectomy hemorrhage, MCS: mental component summary, PCS: physical component 
summary. P-value indicates differences between the incidentaloma en non-incidentaloma group. Bold values 
indicate statistically significant results. * Four missings in body mass index. 
Asymptomatic pancreatic lesions
The rate of asymptomatic lesions amongst patients undergoing distal pancreatectomy 
was 30%. All these lesions were discovered by imaging (abdominal ultrasound (US), 
computed tomography (CT) or magnetic resonance imaging (MRI)). Patients with 
an asymptomatic lesion were significantly older and had shorter follow-up (table 1). 
IPMN appeared to be the final postoperative diagnosis in 39% of the patients with an 
asymptomatic lesion. One patient appeared to have signs of chronic pancreatitis in the 
pathology report, but the lesion was discovered during follow-up after lung cancer and 
thus this lesion was pointed out as asymptomatic.
New-onset diabetes mellitus
Table 2 shows the differences between patients with and without NODM. Six patients 
were diabetic preoperatively. Nineteen patients developed NODM after DP (43%). 
It appeared that IPMN was associated with the onset of NODM and that patients 
with NODM suffered from complications more often. Asymptomatic lesions were not 
significantly associated with the onset of NODM.
Of the 19 patients with NODM, 12 started to use glucose-lowering drugs (63%). Six 
patients used metformin, three used insulin, two used metformin as well as insulin, 
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one used metformin as well as a SU-derivative. The mean duration from DP to onset of 
NODM was 25.9 months (SD 33.6). Eight patients developed early NODM, of whom 
three patients developed NODM directly postoperative during hospital admission. 
Eleven patients developed NODM more than 6 months postoperatively. The latest case 
of NODM developed after almost twelve years. 
Table 2. Differences between the patients with and without new-onset diabetes (NODM). 
No NODM (n=25)  NODM (n=19) P-value
Sex male
female
8 (32%)
17 (68%)
11 (58%)
8 (42%)
0.086
Age 51.9 (SD 12.2) 58.2 (SD 15) 0.129
Body mass index* 24.9 (SD 3.4) 26.2 (SD 3.3) 0.225
Diagnosis
Chronic pancreatitis
Neuroendocrine tumor
Pseudocyst, cystadenoma
IPMN
Mucinous cystic neoplasm
Carcinoma
Other
4 (16%)
11 (44%)
3 (12%)
0 
4 (16%)
1 (4%)
2 (8%)
4 (21%)
5 (26%)
0
8 (42%)
1 (5%)
0
1 (5%) 0.004
Asymptomatic lesion 5 (20%) 8 (42%) 0.111
IPMN no
yes
25 (100%)
0
11 (58%)
8 (42%)
0.000
Operation type body-tail
tail
10 (40%)
15 (60%)
4 (21%)
15 (79%)
0.211
Splenectomy 9 (36%) 6 (32%) 0.759
Laparoscopy 6 (24%) 2 (11%) 0.433 
Complication 3 (12%) 11 (58%) 0.003
Non-fasting glucose (mean) 7 (SD 3.3) 8 (SD 2.8) 0.265
HbA1Cmmol/mol (mean) 43.7 (SD 12.1) 54 (SD 10.2) 0.005
MCS (mean) 77.1 (SD 16.8) 81.8 (SD 16) 0.357
PCS (mean) 75.8 (SD 24) 84 (SD 16.2) 0.188
IPMN: intraductal papillary mucinous neoplasm, MCS: mental component summary, PCS: physical component 
summary. Bold values indicate statistically significant results. Preoperative diabetic patients (n=6) are in the 
analyses as ‘no NODM’. *Four missings in body mass index. 
New exocrine insufficiency 
In one patient the postoperative elastase-1 level was lacking. The mean elastase-1 level 
of the remaining patients was 314 µg/gr (SD 0.18). Table 3 shows the differences 
between the patients with and without new exocrine insufficiency. Three patients used 
enzyme supplements before surgery. Nineteen patients were considered to have exocrine 
insufficiency (43%), of whom eleven patients used supplements (58%). Asymptomatic 
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lesions were not significantly associated with the onset of exocrine insufficiency. 
Splenectomy was associated with the onset of new exocrine insufficiency (P=0.024). 
Eleven patients with exocrine insufficiency had concomitant NODM. NODM and 
exocrine insufficiency were not significantly correlated (P=0.086). 
Table 3. Differences between the patients with and without exocrine insufficiency. 
No new exocrine insufficiency 
(n=25)
New exocrine insufficiency 
(n=19)
P-value
Sex male
female
10 (40%)
15 (60%)
9 (47%)
10 (53%)
0.625
Age 55.5 (SD 12.8) 53.5 (SD 15.1) 0.645
Body mass index* 25.4 (SD 3.1) 25.5 (SD 3.7) 0.973
Diagnosis
Chronic pancreatitis
Neuroendocrine tumor
Pseudocyst, cystadenoma
IPMN
Mucinous cystic neoplasm
Carcinoma
Other
3 (12%)
8 (32%)
0
6 (24%)
4 (16%)
1 (4%)
3 (12%)
5 (26%)
8 (42%)
3 (16%)
2 (11%)
1 (5%)
0
0 0.102
Asymptomatic lesion 9 (36%) 4 (21%) 0.335
IPMN no
yes
19 (76%)
6 (24%)
17 (90%)
2 (11%)
0.433
Operation type body-tail
tail
8 (32%)
17 (68%)
6 (32%)
13 (68%)
0.976
Splenectomy 5 (20%) 10 (53%) 0.024
Laparoscopy 5 (20%) 3 (16%) 1.000 
Complication 5 (20%) 9 (47%) 0.054
Elastase-1 level μg/gr (mean)** 391 (SD 14) 217 (SD 19) 0.001
MCS (mean) 80.5 (SD 15.1) 77.3 (SD 18.4) 0.527
PCS (mean) 77.1 (SD 23) 82.4 (SD 18.5) 0.416
IPMN: intraductal papillary mucinous neoplasm. Bold values indicate statistically significant results. 
Patients using enzyme suppletion preoperatively (n=3) are in the analyses as ‘no new exocrine insufficiency’. 
*Four missings in body mass index. **One missing in elastase-1 levels.
Quality of life 
The mean value of the physical component summary was 79.3 (SD 21.1) and the mental 
component summary was 79.1 (SD 16.5).
Patients with an asymptomatic lesion reported higher scores with regard to their 
mental health compared to symptomatic patients (P=0.023, table 1). The differences 
in quality of life in patients with and without NODM and new exocrine insufficiency 
were not significant (table 2 and 3). Lastly, the mean physical and mental component 
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summary were compared to those of the national Dutch population (17), matched on 
age. The mean age of the asymptomatic patients was 61.8, thus the quality of life of these 
patients was compared with the age group of 61-70 years. For patients with NODM and 
exocrine insufficiency the mean age was 58.2 and 53.5 respectively, thus these patients 
were compared with the age group of 41-60 years. All confidence intervals overlapped, 
indicating non-significant differences between the groups (table 4). 
Table 4. Differences in physical and mental component summary (PCS and MCS) in asymptomatic 
patients, patients with NODM and new exocrine insufficiency, compared to the Dutch population (17).
 Dutch population
61-70yr
(mean (SD), 
95%CI)
Asymptomatic
61-70yr
(mean (SD), 
95%CI)
Dutch population
41-60yr
(mean (SD), 
95%CI)
NODM
41-60yr 
(mean (SD), 
95%CI)
New exocrine insuf-
ficiency
41-60yr
(mean (SD), 95%CI)
PCS 67.8 (27.8)
(13.3-122.3)
85.3 (19.3.6)
(73.7-97)
75 (25.3)
(25.4-124.6)
83.9 (16.2)
(76.1-91.7)
82.4 (18.5)
(73.5-91.3)
MCS 76.9 (24.3)
(29.3-124.5)
87.7 (11.9)
(80.5-94.9)
77.3 (23.5)
(31.2-123.4)
81.8 (16)
(74-89.5)
77.3 (18.4)
(68.4-86.2)
NODM: new onset diabetes mellitus, PCS: physical component summary, MCS: mental component summary. 
Discussion
This case series assessed the rate of asymptomatic pancreatic lesions in a cohort of patients 
undergoing DP for various indications and studied postoperative NODM, exocrine 
insufficiency and quality of life. The overall rate of asymptomatic lesions amongst patients 
undergoing DP in this study was 30%. IPMN was most frequently diagnosed within this 
group (39%). Furthermore, asymptomatic patients were older. 
Other studies investigating asymptomatic pancreatic lesions and surgery reported 
incidence rates varying from 6% to 37% (6, 18-20). Three of these studies also found 
IPMN to be the most frequent diagnosis (3, 6, 19). However, one study only investigated 
pancreaticoduodenectomies and not DPs (6). One study also found higher age among 
asymptomatic patients (19), while two other studies found no differences in age (3, 6). 
Our study did not find differences with regard to complications in the group with an 
asymptomatic lesion. Previous studies are conflicting: one reports higher incidences 
of POPF (6) and another reports lower incidences of POPF (3) among asymptomatic 
patients.
Regarding NODM, the overall rate in our study was 43%. This was largely explained by 
the 42% NODM rate in patients with IPMN, which was significantly associated with 
NODM. This high percentage of NODM is remarkable, since the number of patients 
with chronic pancreatitis (CP) was small in our study. It is seen that the onset of NODM 
is associated with the underlying disease and that NODM occurs most frequently in 
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patients with CP (39%) (11). In our recently published review, the rate of NODM 
among patients with benign or premalignant lesions was found to be much lower (14%) 
(11). Therefore the high percentage of patients with NODM in the IPMN group in this 
study is surprising. However, in our review the numbers of IPMN patients were small and 
were not studied separately. Thus, the present study may have found IPMN, next to CP, 
as a risk factor for NODM after DP.
Regarding new exocrine insufficiency, the overall rate was 43%, without differences 
between groups. Patients undergoing additional splenectomy however, developed new 
exocrine insufficiency more often. Percentages known from existing literature report 
incidences of exocrine dysfunction varying from 18% (21) to 27% (22), and even 
59% (23). The latter study described other procedures next to DP, which could have 
accounted for the higher incidence of exocrine insufficiency as it is known that the 
type of procedure and the extent of the resection correlates with the onset of exocrine 
insufficiency (24). However, information on exocrine insufficiency in patients with 
an asymptomatic pancreatic lesion is scarce, thus this might be an important topic for 
further research. Information on the influence of splenectomy on exocrine insufficiency 
is also limited. One study from 2002 (25) compared DPs with and without splenectomy 
and postoperatively described severe diarrhea in two patients, however the study does not 
tell if this concerned patients in the splenectomy group or not. Most reviews comparing 
(laparoscopic) DPs with or without splenectomy report direct in-hospital complications 
and not exocrine (in)sufficiency (26, 27).
Regarding quality of life, the present study found that patients with an asymptomatic 
lesion reported better mental health. An explanation might be that asymptomatic 
patients suffer from less physical complaints which possibly has a positive influence on 
mental wellbeing. To our knowledge, no studies that specify quality of life in patients 
with asymptomatic pancreatic lesions exist. With regard to quality of life after pancreatic 
resection and pancreatic dysfunction our study did not find any significant differences 
and quality of life was comparable to that of the average Dutch population. A study from 
2013 (28) reported that patients who developed pancreatic dysfunction had a worse 
physical, but not mental component summary . This study also showed that the quality 
of life of patients with pancreatic disease was – and postoperatively remained – lower 
than the quality of life of the normal population. However, a study from 2014 found that 
iatrogenic exocrine insufficiency did not impair quality of life (23). 
An important but difficult aspect of surgery for asymptomatic pancreatic lesions is the 
fact that some harbor malignant potential and some do not. In this series 85% (11 out of 
13) of the asymptomatic lesions had malignant potential. Earlier studies found that 25%-
30% of asymptomatic pancreatic lesions was malignant and almost 50% was a malignant 
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precursor lesion (3, 6). For solid lesions, suspicion of malignancy is high and surgery 
is the preferred treatment. In cystic lesions however, chances for malignancy differ by 
demographic, radiographic and clinical findings and in some patients follow-up would 
be sufficient (7). With IPMN being the most frequent diagnosis among asymptomatic 
lesions, it is important that preoperative distinction between the two main types is made. 
In our study, 25% of the IPMNs was of the main duct type and 25% was of a side-branch 
type. With the main duct type harboring 70% and the side-branch approximately 25% 
malignancy the necessity to surgery differs greatly (7, 29). Patients’ age and tumor size 
should be carefully considered in case of a side-branch IPMN to avoid unnecessary 
operations (29), especially in patients who have an asymptomatic lesion.
Limitations
Some limitations of this study should be addressed. At first, baseline differences with 
regard to age and follow-up between patients with and without an asymptomatic lesion 
were found. Thus, these groups might not be ideally comparable. With regard to quality 
of life it would have been of more value if a pre- and postoperative comparison could 
have been made, especially in patients with an asymptomatic lesion. Due to the partially 
retrospective aspect of this study preoperative information on quality of life was not 
available. However, by comparing quality of life from this study with that of the average 
Dutch population some conclusions could be drawn. Furthermore, the study population 
was relatively small and thus no further associations with regard to onset of NODM or 
exocrine insufficiency could be statistically assessed. Nevertheless, this study provided 
detailed information on patients with an asymptomatic pancreatic lesion and linked this 
to the onset of NODM and exocrine insufficiency and assessed quality of life, which no 
studies on asymptomatic pancreatic lesions have done before. 
To conclude, because of future innovations in diagnostic imaging the incidence of 
asymptomatic pancreatic lesions is likely to increase. Larger studies in patients with 
an asymptomatic pancreatic lesion are needed to assess onset of NODM, exocrine 
insufficiency and quality of life. This, in order to adequately inform patients who are 
planned to undergo DP - especially for asymptomatic lesions - about the possible 
consequences. This is important because diabetes, also in view of the increased life 
expectancy, can become a lifelong complication.
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Summary
Chapter 1 provides the reader with an overview of the major changes in disease 
prevalence that have occurred over the past decades.  The population has become 
increasingly obese and forecasts predict an ongoing increase in the future. Together 
with the rise of obesity the prevalence of the metabolic syndrome (MetS) and type 2 
diabetes mellitus (T2DM) have increased as well, since these three conditions are highly 
related. Common factors of obesity, MetS and T2DM are hyperinsulinemia, altered 
adipocytokine levels and a state of increased inflammation. These factors are thought to 
stimulate carcinogenesis because they have effects on - for instance - cell proliferation, 
apoptosis and angiogenesis. As a result, T2DM has been linked to an increased cancer 
incidence and mortality. This thesis studies the incidence and mortality of breast and 
colorectal cancer among diabetic patients in a meta-analysis. Additionally, detection bias 
and duration of diabetes (DM) were investigated with regard to cancer incidence. In 
esophageal adenocarcinoma the expression of the insulin-like growth factor-1 receptor 
(IGF-1R) and its influence on prognostic parameters was assessed. Also the influence 
of diabetes on the chance of  undergoing surgery for esophageal adenocarcinoma  was 
studied. 
Moreover, diabetes can also occur after distal pancreatectomy (DP). DP is an increasingly 
performed procedure due to enhanced detection of asymptomatic pancreatic lesions. 
In a systematic review we obtained exact percentages of new-onset diabetes (NODM) 
after DP and in a case series we assessed the rate of asymptomatic pancreatic lesions and 
studied the effect of DP on endo-, exocrine pancreatic function and quality of life. 
Chapter 2 describes the results of a meta-analysis investigating the association between 
DM and breast and colorectal cancer incidence and cancer-specific mortality. A total 
of twenty studies, consisting of controlled trials, prospective or pooled cohort studies, 
were included. The studies predominantly comprised patients with type II DM. It was 
seen that patients with diabetes had significantly increased incidences of breast, as well 
as colorectal cancer compared to non-diabetic patients. Also with regard to breast and 
colorectal cancer mortality the diabetic patients experienced higher mortality rates. This 
meta-analysis indicated that DM is a risk factor for breast and colorectal cancer incidence 
and mortality. However, future studies should adjust for diabetes duration and use of 
glucose-lowering drugs. 
In chapter 3 detection bias and duration of DM and the association with cancer 
incidence were studied in more detail in a large cohort of the Rotterdam Study. The 
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total cohort consisted of 10.181 individuals. Incident diabetes was associated with an 
increased overall risk of incident cancers and pancreatic cancer. A diagnosis of diabetes 
less than three months before the diagnosis of cancer was associated with strongly 
increased risks of all- and pancreatic cancers. We concluded that the magnitude of the 
association between diabetes and an increased risk of cancer seemed to be inflated by 
detection- or protopathic bias. However, future studies investigating this association 
should include a plausible aetiological risk window to assess when exactly diabetes has its 
impact in carcinogenesis. 
In Chapter 4 the expression of the insulin-like growth factor-1 receptor (IGF-1R) in 
esophageal adenocarcinoma (EAC) is investigated. The incidence of EAC increases, 
maybe due to the increasing prevalence of obesity and diabetes. Because hyperinsulinemia 
might promote carcinogenesis via the IGF-1R its expression was studied in correlation 
with diabetes and prognostic parameters in patients with EAC. Absence of IGF-1R 
appeared to be associated with T3-, grade 3 tumors and R1 resections. Diabetes was 
not associated with IGF-1R-expression. Furthermore, IGF-1R was present in Barrett 
tissues, but diminished in high-grade dysplasia. Absence of IGF-1R might be a result of 
tumor dedifferentiation. Also, IGF-1R might be an additional tumor marker in Barrett’s 
esophagus, since a change in expression patterns was found in the course from normal 
esophageal tissue to adenocarcinoma.
In Chapter 5 the influence of diabetes on the chance to undergo surgery for EAC and 
mortality is discussed. EAC still has a dismal prognosis and many patients are - often 
because of comorbidities – not eligible for surgery, despite improved surgery techniques. 
Patients were selected from the Eindhoven Cancer Registry; a total of 2729 with EAC 
were included in the study. DM significantly reduced chances of surgery in univariable 
analyses but after adjustment for age this effect disappeared. DM did not have any 
influence on overall mortality. Surgery – unsurprisingly – decreased overall mortality and 
diabetes was not of significant influence on mortality after surgery. The fact that diabetes 
did not have any influence on mortality could be explained by the dismal prognosis of 
EAC. Moreover, the surgeon probably selects the healthiest diabetic patients for surgery. 
In Chapter 6 the results of a systematic review investigating the incidence of new onset-
diabetes after distal pancreatectomy are presented. Postoperative diabetes is a common 
problem after DP, but so far, exact rates were not known. In this review, a total of twenty-
six  studies were included, comprising 1731 patients undergoing DP. The average rate 
of NODM after DP performed for chronic pancreatitis was 39% and for benign or 
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(potentially) malignant lesions it was 14%. The average percentage of insulin-dependent 
diabetes among patients with NODM was 77%. This review showed that NODM is 
a frequently occurring complication, with the incidence depending on the preexisting 
disease. Because NODM can affect quality of life, patients undergoing DP should be 
preoperatively provided with this information as specific as possible.
Distal pancreatectomy is an increasingly performed procedure because of increased 
detection of asymptomatic, potentially (pre)malignant pancreatic lesions. In chapter 
7 the rate of asymptomatic pancreatic lesions is studied in a case series of 44 patients 
who underwent DP. Postoperative endo- and exocrine pancreatic function and quality 
of life was assessed. In 30% the DP was performed for an asymptomatic lesion and 39% 
of asymptomatic lesions were intraductal papillary mucinous neoplasms (IPMN). The 
overall rate of NODM was 43%, with IPMN being significantly associated with NODM. 
New exocrine insufficiency developed in 43% of the patients and asymptomatic patients 
reported better mental health compared to symptomatic patients. Larger studies should 
further assess the harm that might be done to patients who undergo DP because of an 
asymptomatic pancreatic lesion. 
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Hoofdstuk 1 geeft een overzicht van de grote veranderingen op het gebied van ziekte 
prevalentie die zich de afgelopen decennia hebben voorgedaan. De populatie is in 
toenemende mate obees geworden en de voorspelling is dat dit in de toekomst alleen 
maar zal toenemen. Samen met de gestegen prevalentie van obesitas zijn ook de 
prevalentie van het Metabool Syndroom (MetS) en diabetes mellitus type 2 (T2DM) 
toegenomen aangezien deze drie aandoeningen direct aan elkaar verwant zijn. 
Gezamenlijke factoren behorend bij obesitas, MetS en T2DM zijn hyperinsulinemie, 
verhoogde adipocytokine levels en een verhoogde staat van inflammatie. Van deze 
factoren wordt gedacht dat zij de carcinogenese stimuleren, omdat zij allen effect 
hebben op bijvoorbeeld celproliferatie, apoptose en angiogenese. Dit heeft als gevolg dat 
T2DM wordt geassocieerd met een verhoogde kanker incidentie en mortaliteit. In dit 
proefschrift wordt de incidentie en mortaliteit van mamma- en colorectaalcarcinoom 
onder diabeten bestudeerd in een meta-analyse. Aanvullend worden detection bias en de 
duur van diabetes (DM) en hun invloed op kanker incidentie onderzocht. De expressie 
van de insulin-like growth-factor-I receptor (IGF-1R) in het adenocarcinoom van de 
oesophagus wordt bekeken en gecorreleerd aan prognostische parameters. Verder wordt 
nog de invloed van DM op de kans om chirurgie bij een oesophagus adenocarcinoom 
(OAC) te ondergaan onderzocht. 
Daarnaast kan DM ook voorkomen na een distale pancreatectomie (DP). Deze 
operatie wordt in toenemende mate uitgevoerd vanwege een verhoogde detectie van 
asymptomatische laesies in het pancreas. Door middel van een systematisch review 
hebben we exacte percentages van new-onset diabetes (NODM) na DP verkregen en in 
een case serie hebben we gekeken naar het aantal asymptomatische pancreas laesies en 
hebben we het effect van een DP op de endo- en exocriene pancreasfunctie en kwaliteit 
van leven onderzocht. 
Hoofdstuk 2 beschrijft de resultaten van een meta-analyse die de associatie tussen DM 
en de incidentie en mortaliteit van mamma- en colorectaal carcinoom onderzoekt. 
Twintig studies, bestaande uit controlled trials, prospectieve of gepoolde cohort 
studies, werden geïncludeerd. Deze studies bevatten met name patiënten met T2DM. 
Wat werd gezien is dat patiënten met DM een significant verhoogde incidentie van 
mamma- alsmede van colorectaal carcinoom hadden ten opzichte van patiënten 
zonder DM. Ook de mortaliteit van deze twee carcinomen was hoger onder patiënten 
met DM. Deze meta-analyse laat zien dat DM een risicofactor is voor het ontstaan 
van en sterven aan mamma- en colorectaal carcinoom. Toekomstige studies moeten 
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echter nog corrigeren voor de duur van de DM en het gebruik van glucose verlagende 
middelen. 
In hoofdstuk 3 worden detection bias en de duur van DM en de relatie met kanker 
incidentie nader onderzocht in een groot cohort van de Rotterdam Studie. Het totale 
cohort behelst 10.181 patiënten. Incidente DM was geassocieerd met een verhoogd 
overall risico op incidente kankers en pancreas carcinoom. Een DM diagnose minder dan 
drie maanden voor de kanker diagnose was geassocieerd met een sterk verhoogd risico 
op alle en pancreas carcinomen. We concluderen dat een groot deel van de associatie 
tussen DM en het verhoogde kankerrisico wordt veroorzaakt door detection- of 
protopathic bias. Toekomstige studies die deze associatie onderzoeken dienen echter wel 
een etiologisch risico window op te nemen zodat onderzocht kan worden wanneer DM 
precies zijn impact heeft in de carcinogenese. 
In hoofdstuk 4 wordt de expressie van de insulin-like growth factor-1 receptor (IGF-1R) 
in oesophagus adenocarcinoom (OAC) onderzocht. De incidentie van het OAC stijgt, 
mogelijk door de toegenomen prevalentie van obesitas en DM. Omdat hyperinsulinemie 
misschien de carcinogenese stimuleert via de IGF-1R werd de expressie hiervan 
onderzocht en gecorreleerd aan DM en prognostische parameters in patiënten met 
een OAC. Afwezigheid van expressie van IGF-1R was geassocieerd met T3 en graad 3 
tumoren en R1 resecties, met als gevolg een verlaagde vijfjaars overall survival. DM was 
niet geassocieerd met IGF-1R-expressie. Daarnaast was IGF-1R aanwezig in Barrett 
weefsel, maar de expressie nam af in weefsels met hooggradige dysplasie. Afwezigheid 
van IGF-1R is mogelijk een gevolg van tumor dedifferentiatie. IGF-1R kan misschien 
ook gebruikt worden als een tumor marker in Barrett oesophagus, omdat een verschil in 
expressiepatronen werd gevonden in het beloop van normaal oesophagus weefsel tot aan 
een adenocarcinoom. 
In hoofdstuk 5 wordt de invloed van DM op de kans om chirurgie voor OAC te 
ondergaan bestudeerd, evenals de invloed van DM op de mortaliteit. OAC heeft, 
ondanks verbeterde chirurgische technieken, nog steeds een slechte prognose en veel 
patiënten komen niet in aanmerking voor een operatie, vaak vanwege comorbiditeit. 
Vanuit de Eindhoven Cancer Registry (ECR) werden 2729 patiënten met een OAC 
geïncludeerd in de studie. DM reduceerde de kans op chirurgie significant in univariabele 
analyses, maar na correctie voor leeftijd verdween dit effect. DM bleek geen invloed 
te hebben op de overall mortaliteit. Chirurgie verlaagde – niet onverwacht- de overall 
mortaliteit en DM had geen significante invloed op de mortaliteit na chirurgie. Het feit 
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dat DM geen invloed had op de mortaliteit wordt misschien verklaard door de slechte 
prognose van OAC. Daarnaast selecteren chirurgen waarschijnlijk de gezondste diabeten 
om chirurgie te ondergaan. 
Hoofdstuk 6 beschrijft de resultaten van een systematisch review welke de incidentie 
van new-onset diabetes na distale pancreatectomie (DP) onderzoekt. Postoperatieve 
diabetes na DP is een veelvoorkomend probleem, maar desondanks waren tot op heden 
exacte percentages niet bekend. In dit review werden 26 studies geïncludeerd met totaal 
1731 patiënten die een DP ondergingen. Het gemiddelde percentage van NODM na 
DP die voor chronische pancreatitis werd uitgevoerd bedroeg 39%, waar het percentage 
voor benigne of mogelijk (pre)maligne laesies 14% was. Het gemiddelde percentage van 
insuline-afhankelijke diabetes onder de patiënten met NODM bedroeg 77%. Dit review 
liet zien dat NODM een veel voorkomende complicatie is, waarbij de incidentie afhangt 
van de onderliggende ziekte. Omdat NODM de kwaliteit van leven kan aantasten 
moeten patiënten die een DP ondergaan preoperatief zo goed mogelijk geïnformeerd 
worden over deze complicatie. 
Een DP wordt in toenemende mate uitgevoerd vanwege de verhoogde detectie 
van asymptomatische, mogelijk (pre)maligne laesies in het pancreas. Hoofdstuk 7 
bestudeert asymptomatische pancreas laesies in een case serie van 44 patiënten die 
een DP ondergingen. De postoperatieve endo- en exocriene pancreasfunctie en de 
kwaliteit van leven werd in deze groep onderzocht. In 30% van de gevallen was de DP 
uitgevoerd voor een asymptomatische laesie en 39% hiervan betrof een intraductale 
papillaire mucineuze neoplasie (IPMN). Het totale percentage patiënten met NODM 
bedroeg 43%, waarbij IPMN significant geassocieerd was met NODM. Een percentage 
van 43% van de patiënten ontwikkelde nieuwe exocriene insufficiëntie. Daarnaast 
rapporteerden asymptomatische patiënten een betere mentale gezondheid vergeleken met 
symptomatische patiënten. In de toekomst dienen grotere studies de mogelijke schade die 
patiënten kunnen ondervinden van een DP die uitgevoerd is voor een asymptomatische 
pancreaslaesie nader te onderzoeken. 
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General discussion and future perspectives
With the tremendous increase of obesity in the worldwide population and a subsequent 
increase of type 2 diabetes mellitus (T2DM) (1, 2) attention has gone out the possible 
association between T2DM and cancer incidence and cancer mortality. The numerous 
studies that have been published on this topic initially caused some panic among 
physicians. However, later on it appeared that most of the studies did not account for 
some important biases that can be present in studying the diabetes-cancer link (3-5). 
In this thesis we aimed to investigate aspects that had not yet been sufficiently 
investigated with regard to diabetes and incidence and prognosis of surgical malignancies. 
Additionally, the influence of pancreatic surgery on pancreatic function and new-onset 
diabetes (NODM) was studied in more detail. 
T2DM and cancer incidence, prognosis and future perspectives
During the past few years, a large body of evidence has indicated a strong association 
with T2DM and cancer incidence. All cancers combined, pancreas, liver, colorectal, 
(postmenopausal) breast, kidney, bladder and endometrial cancer have been consistently 
associated with T2DM (3, 5, 6). However, a large part of the association is influenced by 
detection bias as shown in this thesis. The risk is particularly increased in the period just 
after the diabetes (DM) diagnosis, which can indicate increased medical surveillance, as 
described in this thesis and other studies (7-9). However after this first period, risks for 
cancer among DM patients remain increased - yet somewhat declined (3, 9). Regarding 
liver and pancreatic cancer the association is largely due to reversed causality with the 
cancer initiating DM (3, 6). What needs to be investigated in more detail is the so-called 
latency or sojourn period that is present in carcinogenesis (10, 11). Because this period 
differs per cancer type it is difficult to determine a correct aetiological risk window and to 
analyse when diabetes has its possible impact on carcinogenesis. 
With regard to cancer mortality, it is important to distinguish all-cause and cancer-
specific mortality. Our meta-analysis proved that DM increased breast and colorectal 
cancer-specific mortality. It has been seen that cancer incidence and cancer-related 
mortality are not interchangeable (4). For colorectal, liver, pancreas and bladder positive 
associations with regard to cancer mortality have been found (12-15). However, for 
breast and endometrial cancer results are somewhat inconsistent (12, 14). 
When studying the link between T2DM and cancer mortality, one should account for 
several biases that can occur, for example the possible diminished use of cancer screening 
among diabetics (16-18), more advanced tumour stage at diagnosis (19, 20) and selection 
bias for cancer treatment (21, 22). This thesis assessed the chance of undergoing surgery 
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for esophageal adenocarcinoma and found that probably only the healthiest diabetic 
patients are selected for surgery. With regard to mortality DM had no influence in 
patients with esophageal adenocarcinoma. This is probably because of the grim prognosis 
of esophageal adenocarcinoma and thus DM cannot be a competing cause of death. This 
reflects in the fact that other studies proved that excess mortality with DM was mostly 
seen in cancer types with long survival rates (23, 24).
With regard to the insulin-like growth factor receptor-1 (IGF-1R) its expression has 
been described in a majority of solid tumours (25). Concerning the influence of IGF-1R 
expression on cancer progression and prognosis, results are not completely consistent 
among the different cancer types. Some studies find that an increased expression of IGF-
1R correlates with worse prognosis (26-28), while other studies consider IGF-1R as a 
good prognostic marker (29, 30). It is important to investigate whether IGF-1R could 
function as a prognostic marker in tumour tissue, which might be the case as shown in 
this thesis where we describe a high expression of IGF-1R in Barrett’s esophagus. This 
is also important in the light of IGF-1R inhibiting therapies, which have been more 
closely investigated during the past years. Several studied approaches include monoclonal 
antibodies and tyrosine kinase inhibitors ligand binding antibodies (31, 32). Patients 
with tumours that express 1GF-1R might benefit from these kinds of therapies, however 
more studies are needed to find suitable biomarkers and to study adverse effects and 
interactions with normal cancer treatment regimens in more detail (31, 32, 33). 
An important issue that has not been addressed in this thesis is the influence of 
glucose-lowering drugs (like metformin) and cancer risk and cancer mortality. Initially, 
metformin was found to decrease cancer risk (34-36). However, most of these studies 
did not take into account important biases with the result that the protective effect 
of metformin was probably exaggerated. Thus, true treatment and duration effects of 
metformin are not clear yet and more, well-conducted epidemiological studies are needed 
before metformin will be associated with a decreased cancer incidence (37-39).
To conclude, the link between T2DM and cancer incidence and mortality has been 
established, however some aspects still need more careful investigation. Despite this 
established link cancer screening among all diabetics might be too premature. Only in 
case of pancreatic or liver cancer, where the cancer is associated with the onset of DM it 
might be beneficial to screen patients. For instance, patients who do not carry normal risk 
factors for diabetes but do develop this disease might be candidates for pancreas or liver 
cancer screening. With regard to other cancers screening of all diabetic patients might 
not yet provide enough benefits and is probably too costly. A first improvement however, 
could be the reassurance of screening of diabetic patients whom belong to an eligible 
screening population (e.g. breast or cervical cancer screening due to a certain age). As 
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described above, diabetic patients undergo less screening and finding out which factors 
contribute to this phenomenon might lead to a first improvement. 
Nevertheless, we think that the problem of obesity and subsequent T2DM must be dealt 
with from its origin. This thesis emphasizes once more the need for a globally increased 
awareness with regard to prevention of obesity and T2DM. Especially since it has been 
seen that not only adults, but also children have become increasingly obese with 42 
million children under the age of 5 being overweight or obese in 2013 (40). Furthermore, 
overweight and obesity were first considered problems of high-income countries, but 
are now becoming increasingly prevalent in low- and middle income countries, thereby 
additionally contributing to the increase in childhood overweight and obesity (40). 
The World-Health Organization (WHO) has identified priorities for population-based 
strategies to prevent childhood obesity. Interventions with regard to dietary patterns 
and physical activity must take place at national, sub-national and local levels in order 
to achieve desired effects (41). Especially in low- and middle-income countries where 
health care is less developed more possibilities with regard to prevention should be 
created. Otherwise the increase of obesity and T2DM will have ongoing and detrimental 
effects on health care, accompanying costs and the health of the global population. By 
preventing obesity and subsequent T2DM an increase in cancer occurrence and cancer 
mortality might be prevented. 
In the case of existing diabetes, treatment should be as strict as possible, to reassure well-
controlled diabetes. In this way physicians should reduce the chance of complications due 
to diabetes and maybe prevent the onset of cancer. 
Diabetes following pancreatic surgery 
Enhanced detection of asymptomatic pancreatic lesions leads to increased rates of 
pancreatic resections, mainly distal pancreatectomies (DPs) (42). Since a large amount of 
these incidentally discovered lesions harbor malignant potential (42, 43), surgery can be 
of great importance. However, in case of lesions that might not require surgery, like side-
branch intraductal papillary mucinous neoplasms (SB-IPMN), it is important to perform 
careful preoperative examinations. In this way unnecessarily performed surgery can be 
prevented. Especially since we showed in this thesis that the incidence of new-onset 
diabetes (NODM) can be very high after DP and that IPMN might be associated with 
the onset of NODM. 
With an expected ongoing increased detection of asymptomatic pancreatic lesions, for 
example due to the use of total-body scans, enhanced screening and future innovations, 
other procedures next to DP should be investigated. For instance central pancreatectomy 
(CP). Rates of NODM after CP are reported to be lower compared to DP however, rates 
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of pancreatic fistula are higher (44, 45). Furthermore, the risk of a nonradical resection is 
present in CP when resected lesions postoperatively appear to be malignant.
DP cannot be avoided yet and thus NODM will remain a common complication after 
DP. Surgeons should be aware of the harm they might inflict on patients and they should 
clearly inform patients about this diabetes risk before they undergo surgery. With the 
results of our meta-analysis, patients can now be more accurately informed. However, it 
is unknown whether the relative high percentage of NODM in the literature after DP is 
due to obesity and preoperative hyperinsulinemia of most patients. Again, an increased 
awareness with regard to prevention of obesity might prevent this harmful complication 
in these patients. 
With regard to future perspectives on this topic diabetes after pancreatic surgery might 
be prevented with the help of islet autotransplantation (IAT). IAT has been performed 
in cases after partial or total pancreatectomy in patients with chronic pancreatitis (46, 
47). Possibly, by extending the indications for IAT, the problem of brittle NODM after 
surgery in patients who undergo extensive pancreatectomy for benign or (potentially) 
malignant pancreatic disease might be postponed or even prevented (46, 48). However, 
more data on this topic should be gained before implementing this into daily surgical 
practice. 
To conclude, the diabetes-cancer links does exist, but detection bias accounts for the 
largest part of the increased cancer incidence. Diabetes increases the mortality of breast 
and colorectal cancer, but more studies are needed to definitively establish mortality 
rates per cancer type among patients with diabetes. The IGF-1R, which is activated 
by insulin, might serve as a prognostic marker in Barrett’s esophagus and esophageal 
adenocarcinoma and should further be studied, also in other cancers. Diabetic patients 
are thought to receive less or less aggressive treatment for cancer, however in this thesis 
diabetes did not decrease chances for surgery in esophageal adenocarcinoma.
With regard to pancreatic surgery and diabetes, this thesis describes exact numbers of 
NODM after distal pancreatectomy. This aids physicians in carefully informing their 
patients before surgery, especially when it comes to patients with an asymptomatic 
pancreatic lesion. In the light of diabetes and cancer, ways to prevent NODM after DP 
should be found. 
Most important of all, great attention should go out to the prevention of obesity and 
subsequent diabetes in a world where these diseases have become - and account for - 
major health issues. 
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